Primary Biliary Cirrhosis
Primary biliary cirrhosis is a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventually cirrhosis.
Primary Biliary Cholangitis (PBC) — formerly called Primary Biliary Cirrhosis (the name was changed in 2015 to reflect the fact that most patients are now diagnosed before cirrhosis develops) — is a chronic, progressive, autoimmune cholestatic liver disease characterised by a T-lymphocyte–mediated attack on small intrahepatic (interlobular) bile ducts [1][2].
Let's break down the name:
- Primary → the disease arises de novo from autoimmune mechanisms, not secondary to stones, strictures, or external compression.
- Biliary → targets the bile ducts (specifically the small/medium intrahepatic interlobular bile ducts, < 100 µm).
- Cholangitis → "chol-" = bile, "-ang-" = vessel/duct, "-itis" = inflammation. So: inflammation of the bile ducts.
The sustained, granulomatous destruction of these bile ductules leads to progressive cholestasis (impaired bile flow), then biliary fibrosis, and ultimately liver cirrhosis and liver failure if untreated [1].
Key Concept
PBC is an autoimmune destruction of small intrahepatic bile ducts (interlobular ducts). This is fundamentally different from Primary Sclerosing Cholangitis (PSC), which targets large intrahepatic and extrahepatic bile ducts with fibrotic stricturing. The distinction matters for diagnosis, associations, and management.
Epidemiology
- Global prevalence: approximately 1.9–40.2 per 100,000 population (varies by region; highest in Northern Europe and North America) [3].
- Incidence appears to be increasing, partly due to earlier diagnosis from routine liver function testing.
- In Hong Kong and Asia, PBC is less common than in Western populations but is increasingly recognised. In HK, chronic Hepatitis B remains the dominant cause of liver cirrhosis (~90%), with PBC representing a small but important subset of biliary causes of cirrhosis [2][4].
- Extreme female predominance (90–95% female) [1][2].
- Why? The precise reason is unclear, but leading hypotheses include:
- X-chromosome monosomy: Enhanced X chromosome loss in lymphocytes of PBC patients → disinhibition of X-linked immune regulatory genes.
- Oestrogen effects on immune regulation: Oestrogen modulates T-cell and B-cell function, potentially promoting loss of tolerance to mitochondrial antigens.
- Microchimerism: Fetal cells persisting in maternal circulation post-pregnancy may trigger graft-vs-host–like immune reactions against biliary epithelium.
- Why? The precise reason is unclear, but leading hypotheses include:
- Age of diagnosis: typically 30–65 years (middle-aged women) [1].
- Rarely diagnosed before 25 or after 70.
- Highest prevalence in Northern Europe (UK, Scandinavia) and North America.
- Lower prevalence in Asia and Africa, though increasingly diagnosed.
- Clustering in families: first-degree relatives of PBC patients have a ~100-fold increased risk.
| Risk Factor | Mechanism / Explanation |
|---|---|
| Female sex | ~9:1 female-to-male ratio; X-chromosome and hormonal mechanisms |
| Family history of PBC | Concordance rate ~63% in monozygotic twins; strong genetic component |
| HLA associations | HLA-DRB108 (risk), HLA-DRB111 (protective) |
| Other autoimmune diseases | PBC clusters with other autoimmune conditions (see below) |
| Recurrent urinary tract infections | Molecular mimicry: E. coli pyruvate dehydrogenase complex (PDC-E2) shares epitopes with human mitochondrial PDC-E2, triggering cross-reactive autoimmunity |
| Smoking | Dose-dependent increased risk; mechanism may involve oxidative modification of mitochondrial antigens |
| Environmental chemicals | Xenobiotics (e.g., halogenated hydrocarbons, nail polish chemicals like 2-octynoic acid) can modify PDC-E2 → neoantigen formation → immune attack |
| Prior pregnancies | Related to microchimerism hypothesis |
Molecular Mimicry — The Key Pathogenetic Concept
The E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), located on the inner mitochondrial membrane, is the primary autoantigen in PBC. Certain bacteria (especially E. coli) have PDC-E2 homologues. Repeated UTIs may trigger cross-reactive immune responses in genetically susceptible individuals → loss of tolerance → autoimmune destruction of biliary epithelial cells (which uniquely express PDC-E2 on their apical surface after apoptosis, unlike most other cell types where PDC-E2 is cleaved during apoptosis).
PBC is strongly associated with other autoimmune diseases. Think of PBC as part of an "autoimmune constellation" [1]:
| Associated Condition | Prevalence in PBC | Notes |
|---|---|---|
| Sjögren's syndrome | 40–65% | Sicca symptoms (dry eyes, dry mouth); most common association |
| Hashimoto's thyroiditis | 10–15% | Screen with TFT at diagnosis |
| Systemic sclerosis (Scleroderma) | 5–10% | Especially CREST variant |
| Rheumatoid arthritis | 5–10% | |
| Coeliac disease | ~6% | Screen if diarrhoea or malabsorption disproportionate to cholestasis |
| Raynaud's phenomenon | Common | Due to overlap with systemic sclerosis |
| Autoimmune hepatitis (AIH) | Overlap syndrome in ~10% | "PBC-AIH overlap" — important diagnostic consideration |
| Renal tubular acidosis (Type 1) | Rare | Autoimmune tubular damage |
High Yield — Autoimmune Associations
A common exam pitfall: Students forget to screen for thyroid disease and Sjögren's syndrome in PBC. Always check TFT and ask about sicca symptoms. Sjögren's is the most common autoimmune association (up to 65%).
Anatomy and Function — The Biliary System
To understand PBC, you must understand which bile ducts are targeted and why their destruction matters.
Hepatocytes → Bile canaliculi → Canals of Hering → Cholangioles →
Interlobular bile ducts (< 100 µm) → Septal bile ducts →
Intrahepatic bile ducts → Right and Left hepatic ducts →
Common hepatic duct → (+ cystic duct) → Common bile duct → Ampulla of VaterPBC targets the small interlobular bile ducts (those within the portal triads, < 100 µm diameter). These are lined by biliary epithelial cells (BECs / cholangiocytes).
- Bile formation: Hepatocytes produce bile and secrete it into canaliculi. Bile flows through the duct system to the intestine.
- Bile duct destruction → bile cannot flow out of the liver → cholestasis (bile stasis within the liver).
- Retained bile acids are toxic to hepatocytes → ongoing hepatocyte injury → inflammation → fibrosis → cirrhosis.
- Lack of bile in the intestine → impaired fat emulsification → steatorrhoea → malabsorption of fat-soluble vitamins (A, D, E, K).
Each portal triad contains:
- Hepatic artery branch
- Portal vein branch
- Bile duct (interlobular) ← THIS is the target in PBC
The classic histological lesion of PBC — the "florid duct lesion" — shows lymphocytic infiltration and granulomatous destruction centred on these portal triad bile ducts.
Etiology and Pathophysiology
PBC is an autoimmune disease of unknown precise aetiology, arising from a combination of:
-
Genetic susceptibility
- HLA associations: HLA-DRB108 (susceptibility), HLA-DRB111, HLA-DRB1*13 (protective)
- Non-HLA genes: IL-12A, IL-12RB2, STAT4, IRF5, CTLA-4, TNFSF15
- Strong familial clustering; ~63% concordance in monozygotic twins
-
Environmental triggers
- Molecular mimicry (bacterial PDC-E2, especially from E. coli)
- Xenobiotics (halogenated compounds that modify PDC-E2 → neoantigen)
- Smoking
- Possibly hormonal factors (explaining female predominance)
-
Loss of immune tolerance
- The central autoantigen is PDC-E2 (E2 subunit of the pyruvate dehydrogenase complex), located on the inner mitochondrial membrane
- In PBC, biliary epithelial cells (BECs) are unique: when BECs undergo apoptosis, PDC-E2 remains immunologically intact on apoptotic blebs (it is not glutathionylated/cleaved as in other cell types)
- This intact PDC-E2 is presented to the immune system → T-cell and B-cell activation → autoimmune attack specifically on BECs
-
Humoral immunity:
- Anti-mitochondrial antibodies (AMA) — specifically AMA-M2 targeting PDC-E2 — are the serological hallmark (present in ~95% of PBC patients) [1]
- AMA are highly specific (~98%) but are NOT directly pathogenic; they are a marker of the underlying autoimmune process
- Other AMA subtypes (M4, M8, M9) are less commonly tested
-
Cellular immunity (the actual effector mechanism):
- CD4+ T-helper cells and CD8+ cytotoxic T cells infiltrate the portal tracts and directly attack BECs
- The granulomatous inflammation around damaged ducts is the hallmark histological feature
- CD8+ T cells are the primary effectors of BEC destruction
-
Biliary epithelial cell (BEC) biology:
- BECs in PBC show increased apoptosis
- Unique failure to cleave PDC-E2 during apoptosis → persistent antigen exposure
- BECs also express MHC class II molecules and can act as antigen-presenting cells, amplifying the immune response
- Progressive BEC loss → ductopenia (vanishing bile duct syndrome) → cholestasis
Once bile ducts are destroyed and cholestasis develops:
| Consequence | Mechanism |
|---|---|
| Pruritus | Retained bile acids (and possibly lysophosphatidic acid via autotaxin) stimulate itch receptors in skin; pruritogens accumulate due to impaired biliary excretion |
| Jaundice | Both conjugated and unconjugated bilirubin accumulate; conjugated bilirubin regurgitates into blood from damaged bile ducts |
| Steatorrhoea | Reduced bile acid delivery to intestine → impaired micelle formation → fat malabsorption |
| Vitamin A deficiency | Fat-soluble vitamin malabsorption → night blindness, xerophthalmia |
| Vitamin D deficiency | Fat-soluble vitamin malabsorption → osteomalacia, contributes to osteoporosis |
| Vitamin E deficiency | Fat-soluble vitamin malabsorption → neurological dysfunction (rare) |
| Vitamin K deficiency | Fat-soluble vitamin malabsorption → coagulopathy (prolonged PT/INR) |
| Hyperlipidaemia | Cholesterol is normally excreted in bile; cholestasis → retained cholesterol; also ↑HDL and lipoprotein-X |
| Xanthomata/Xanthelasma | Deposition of lipid-laden macrophages in skin/tendons due to hyperlipidaemia |
| Hyperpigmentation | Melanin deposition (NOT bilirubin) — mechanism unclear but may relate to MSH-like peptides or bile acid–stimulated melanogenesis |
| Hepatic osteodystrophy | Retained toxins inhibit osteoblast function → osteoporosis; vitamin D malabsorption → osteomalacia |
Why Hyperpigmentation in PBC?
A common misconception: the skin darkening in PBC is NOT from jaundice/bilirubin. It is from melanin deposition [1]. The exact mechanism is debated, but it may involve bile acid–mediated stimulation of melanocyte activity or MSH-like peptide release. The pigmentation can be generalised but is often most prominent on sun-exposed areas.
Classification
PBC is classically staged 0–4 based on liver biopsy [1][2]:
| Stage | Name | Histological Features |
|---|---|---|
| Stage 0 | Normal | Normal liver histology |
| Stage 1 | Portal stage | Inflammation and/or abnormal connective tissue confined to portal areas; "florid duct lesion" — granulomatous destruction of interlobular bile ducts; lymphocytic infiltrate around damaged ducts |
| Stage 2 | Periportal stage | Inflammation and/or fibrosis confined to portal and periportal areas; proliferation of small bile ductules (ductular reaction); interface hepatitis may be seen |
| Stage 3 | Septal stage | Bridging fibrosis — fibrous septa linking portal tracts; progressive ductopenia |
| Stage 4 | Cirrhosis | Cirrhosis — regenerative nodules, complete architectural distortion |
Liver Biopsy in PBC
Liver biopsy is often NOT required to establish the diagnosis of PBC [1] when ALP is elevated and AMA is positive. However, it is indicated if: the diagnosis is in doubt, there is evidence of autoimmune hepatitis overlap, or the patient is not responding optimally to ursodeoxycholic acid (UDCA) [1]. Biopsy also provides useful prognostic information through staging.
Some clinicians also classify PBC by clinical stage:
- Pre-clinical — AMA positive, normal LFTs, asymptomatic
- Asymptomatic — AMA positive, abnormal LFTs (↑ALP), no symptoms
- Symptomatic — pruritus, fatigue, jaundice
- Decompensated — cirrhosis with portal hypertension, ascites, variceal bleeding, hepatic encephalopathy
About 5% of patients have typical clinical, biochemical, and histological features of PBC but are AMA-negative. In these patients:
- PBC-specific ANA patterns (multiple nuclear dots [anti-sp100] or rim-like/membranous [anti-gp210]) are often present
- The disease behaves identically to AMA-positive PBC
- Previously termed "autoimmune cholangitis"
~10% of PBC patients have features of both PBC and autoimmune hepatitis (AIH):
- Elevated transaminases (ALT > 5× ULN) in addition to cholestatic pattern
- Interface hepatitis on biopsy
- May be ANA-positive
- Requires combined treatment (UDCA + immunosuppression)
Clinical Features
Asymptomatic at diagnosis in 50–60% of cases [1] — often detected incidentally through raised ALP on routine blood tests.
| Symptom | Frequency | Pathophysiological Basis |
|---|---|---|
| Pruritus | Most common symptom (~70% of symptomatic patients) | Cholestasis → accumulation of pruritogens (bile acids, lysophosphatidic acid via autotaxin enzyme) → activation of itch receptors (TGR5, MRGPRX4) in skin nerve fibres. Worse at night [1]. Often precedes the development of jaundice [1]. Can be severely debilitating. |
| Fatigue | Very common (~80%) | Poorly understood; may involve central mechanisms (altered neurotransmission — serotonergic and corticotropin pathways), autonomic dysfunction, sleep disturbance from pruritus, and cytokine-mediated effects. Does NOT correlate with disease severity. Does NOT improve with liver transplantation in many cases. |
| Steatorrhoea | Variable | ↓ Bile acid secretion into intestine [1] → impaired micelle formation → fat malabsorption → pale, bulky, foul-smelling, floating stools |
| RUQ discomfort | Common | Hepatomegaly → distension of Glisson's capsule (the liver itself has no pain fibres; pain comes from capsular stretch) |
| Dry eyes and dry mouth (sicca symptoms) | 40–65% | Associated Sjögren's syndrome → autoimmune destruction of lacrimal and salivary glands |
| Arthralgia | Variable | Associated autoimmune conditions (RA, Sjögren's) |
| Weight loss | Late feature | Fat malabsorption, anorexia from advanced liver disease |
| Bone pain / fractures | Late | Hepatic osteodystrophy (osteoporosis/osteomalacia from vitamin D deficiency and direct osteoblast inhibition) |
| Night blindness | Late | Vitamin A deficiency from fat malabsorption |
| Easy bruising / bleeding | Late | Vitamin K deficiency → impaired synthesis of clotting factors II, VII, IX, X |
Pruritus in PBC — More Than Just Bile Acids
The mechanism of pruritus in cholestasis has evolved. While bile acids were the traditional explanation, current evidence implicates autotaxin (an enzyme that produces lysophosphatidic acid, LPA) as a key mediator. Serum autotaxin levels correlate with itch severity. This is why cholestyramine (a bile acid sequestrant) helps but doesn't fully relieve itch in all patients, and why IBAT inhibitors (ileal bile acid transporter inhibitors, e.g., linerixibat) and opioid antagonists (naltrexone) may also be effective.
| Sign | Pathophysiological Basis |
|---|---|
| Jaundice | Typically a late manifestation [1]; reflects severe ductopenia and cholestasis → bilirubin accumulation. Both conjugated and unconjugated bilirubin elevated. Elevated serum bilirubin is a poor prognostic sign [1]. |
| Hyperpigmentation | Melanin deposition (NOT bilirubin) [1]. Diffuse, often more prominent in sun-exposed areas. Mechanism debated but may involve bile acid–stimulated melanogenesis. |
| Xanthomata and xanthelasma | Hyperlipidaemia [1] → lipid deposition. Xanthelasma = yellowish plaques around eyelids. Xanthomata = lipid deposits in tendons, skin creases. |
| Hepatomegaly | Becomes more common as PBC progresses [1]; initially due to cholestatic swelling, later due to fibrosis/cirrhosis with regenerative nodules |
| Splenomegaly | Becomes more common as PBC progresses [1]; reflects portal hypertension from progressive fibrosis/cirrhosis. Incidence appears to be decreasing probably because PBC is diagnosed in earlier stages than in the past [1]. |
| Excoriations | Secondary to scratching from severe pruritus |
| Kayser-Fleischer–like rings | Rare; copper deposition in Descemet's membrane (copper is normally excreted in bile; cholestasis → copper retention — but this does NOT indicate Wilson's disease) |
| Spider angiomata | Late; reflect hyperestrogenism from impaired hepatic oestrogen metabolism in cirrhosis |
| Palmar erythema (liver palms) | Late; hyperestrogenism in cirrhosis |
| Ascites | Late (decompensated cirrhosis); portal hypertension → increased hydrostatic pressure in splanchnic capillaries + hypoalbuminaemia → transudative fluid accumulation |
| Peripheral oedema | Late; hypoalbuminaemia + portal hypertension |
Physical Signs — Early vs Late
A common exam mistake: listing jaundice and ascites as early features of PBC. In reality, jaundice is typically a late manifestation [1] and ascites only occurs with decompensated cirrhosis. The early signs are excoriations (from pruritus), hyperpigmentation, and possibly xanthelasma. If a patient has jaundice at presentation, the disease is already advanced and carries a worse prognosis.
When PBC progresses to cirrhosis, all the general signs of chronic liver disease and portal hypertension may be seen [1][2]:
- Ascites — portal hypertension + hypoalbuminaemia
- Variceal bleeding — porto-systemic collaterals (oesophageal varices, rectal varices, caput medusae)
- Hepatic encephalopathy — failure of hepatic ammonia clearance + portosystemic shunting → ammonia and other neurotoxins reach the brain
- Coagulopathy — impaired synthesis of clotting factors + vitamin K malabsorption
- Hepatorenal syndrome — splanchnic vasodilation in cirrhosis → renal hypoperfusion → functional renal failure
Case Illustration — From the Felix Notes
The case in the senior notes [1] beautifully illustrates PBC progression: a 50-year-old woman with abnormal LFTs → pruritus → liver biopsy showing bile duct destruction → UDCA treatment → progressive ascites requiring paracentesis → hepatic encephalopathy after protein load → referral for liver transplantation. This represents the full natural history from diagnosis to decompensation.
Since PBC and PSC are the two major autoimmune biliary diseases, exam questions frequently test their differentiation:
| Feature | PBC | PSC |
|---|---|---|
| Sex | 90–95% Female | 70% Male |
| Age | 30–65 | 30–40 |
| Target ducts | Small intrahepatic interlobular ducts | Large intra- and extrahepatic ducts |
| Associated disease | Sjögren's, thyroid disease, scleroderma | Ulcerative colitis (70–80%) [3] |
| Serological marker | AMA (95% positive) | pANCA (80% positive); AMA negative |
| Cholangiography | Normal (small ducts not visible) | "Beading" — multifocal strictures and dilatations |
| Histology | Granulomatous duct destruction (florid duct lesion) | "Onion-skin" periductal fibrosis |
| Cancer risk | HCC (if cirrhosis) | Cholangiocarcinoma (10–15% lifetime risk) |
| Treatment | UDCA (proven benefit) | UDCA (less proven benefit); liver transplant |
| Prognosis | Better with UDCA; transplant if needed | Worse; high cholangioCA risk |
High Yield Summary
Primary Biliary Cholangitis (PBC) — Key Points for Exams:
-
Definition: Autoimmune T-cell mediated destruction of small intrahepatic interlobular bile ducts → cholestasis → fibrosis → cirrhosis.
-
Epidemiology: 90–95% female, age 30–65, less common in HK than in Western populations.
-
Autoantigen: PDC-E2 (pyruvate dehydrogenase complex E2 subunit) on inner mitochondrial membrane.
-
Serological hallmark: AMA (anti-mitochondrial antibody) positive in ~95%; AMA-M2 subtype is most specific.
-
Key associations: Sjögren's (40–65%) > Hashimoto's (10–15%) > Scleroderma (5–10%) > RA (5–10%).
-
Clinical presentation: 50–60% asymptomatic at diagnosis. When symptomatic: pruritus (most common, worse at night, precedes jaundice) and fatigue. Jaundice is a late and poor prognostic sign.
-
Physical signs: Excoriations, hyperpigmentation (melanin, NOT bilirubin), xanthomata, hepato-splenomegaly (late).
-
Histological staging: 0 (normal) → 1 (portal inflammation, florid duct lesion) → 2 (periportal) → 3 (bridging fibrosis) → 4 (cirrhosis).
-
Diagnostic criteria: ≥ 2 of: (a) ALP ≥ 1.5× ULN, (b) AMA ≥ 1:40, (c) Histological evidence. No extrahepatic biliary obstruction.
-
Complications: All complications of cirrhosis + specific: pruritus, steatorrhoea, fat-soluble vitamin deficiency, hepatic osteodystrophy, hyperlipidaemia, HCC risk.
-
PBC vs PSC: PBC = female, small ducts, AMA+, Sjögren's. PSC = male, large ducts, pANCA+, UC, cholangioCA risk.
Active Recall - Primary Biliary Cholangitis (Definition, Epidemiology, Pathophysiology, Clinical Features)
[1] Senior notes: felixlai.md (Primary Biliary Cholangitis section, pages 532–539) [2] Senior notes: maxim.md (Hepatocellular carcinoma section — PBC as risk factor for cirrhosis/HCC; Acute cholangitis section — PBC as cause of strictures) [3] Senior notes: felixlai.md (Primary Sclerosing Cholangitis section, pages 529–532) [4] Senior notes: felixlai.md (Liver Cirrhosis section — HBV as most common cause in HK, PBC as biliary cause)
Differential Diagnosis of Primary Biliary Cholangitis
Before we list differentials, let's understand what clinical scenario forces you to consider PBC in the first place. There are really two clinical doorways through which PBC enters your differential:
- The incidental cholestatic LFT pattern: A middle-aged woman with raised ALP/GGT, normal or mildly raised transaminases, and no obvious biliary obstruction on ultrasound. What is this?
- The symptomatic cholestatic patient: Pruritus ± fatigue ± jaundice, with or without hepatomegaly. What is causing this?
Both scenarios demand the same thought process: systematically exclude other causes of cholestasis — both intrahepatic and extrahepatic — before landing on PBC.
Fundamental Principle
PBC is a diagnosis of intrahepatic cholestasis. The first and most critical step is to exclude extrahepatic biliary obstruction (stones, strictures, tumours) using imaging (USG ± MRCP). Only after extrahepatic obstruction is excluded do you work through the intrahepatic causes. This is why the diagnostic criteria for PBC explicitly state: "no extrahepatic biliary obstruction" [1].
Framework: Differential Diagnosis by Clinical Presentation
The DDx of PBC maps onto three overlapping clinical scenarios. Let's work through each systematically.
This is the most common way PBC presents — often as an incidental finding. Your differential here is essentially "What causes a cholestatic biochemical pattern?"
| Category | Condition | Key Distinguishing Features | Why It Mimics PBC |
|---|---|---|---|
| Autoimmune biliary | Primary Sclerosing Cholangitis (PSC) [3] | Male predominance (70%), STRONG association with UC [3], pANCA+, AMA−, MRCP shows "beading" of large ducts | Both cause chronic cholestasis with ↑ALP; both are autoimmune |
| Autoimmune biliary | IgG4-associated cholangitis (IgG4-SC) | Elderly males, elevated serum IgG4, associated with autoimmune pancreatitis, responds to steroids | Can cause strictures and cholestasis mimicking PSC or PBC |
| Autoimmune hepatic | Autoimmune Hepatitis (AIH) | Higher transaminases (ALT/AST > 5× ULN), +ve ANA/SMA/LKM, hypergammaglobulinaemia (IgG), interface hepatitis on biopsy | ANA can be positive in both PBC and AIH; PBC-AIH overlap syndrome exists [1] |
| Drug-induced | Drug-induced cholestasis | Temporal relationship with drug initiation (e.g., amoxicillin-clavulanate, erythromycin, chlorpromazine, OCPs, anabolic steroids, co-trimoxazole) | Can give identical cholestatic LFT pattern; AMA negative |
| Infiltrative | Sarcoidosis | Non-caseating granulomas in liver; may have pulmonary sarcoid, raised ACE, hypercalcaemia | Granulomatous hepatitis can mimic PBC histologically; AMA negative |
| Infiltrative | Hepatic amyloidosis | Massive hepatomegaly, raised ALP, systemic amyloidosis features | Cholestatic pattern with hepatomegaly |
| Genetic | Benign recurrent intrahepatic cholestasis (BRIC) | Episodic jaundice and pruritus with complete resolution between episodes; normal GGT (in BRIC type 1) | Pruritus + cholestasis in young patients |
| Genetic | Progressive familial intrahepatic cholestasis (PFIC) | Childhood onset; low GGT (type 1 and 2); genetic testing confirms | Paediatric; not a realistic DDx in middle-aged women |
| Malignant | Intrahepatic cholangiocarcinoma [7] | Mass lesion on imaging; CA 19-9 elevated; CK7+; older patients, weight loss | Can cause intrahepatic cholestasis; PSC is a risk factor |
| Malignant | HCC with intrahepatic bile duct compression [5] | AFP elevated; arterial enhancement on CT/MRI; cirrhotic background (usually HBV in HK) | Cholestasis from mass effect |
| Vascular | Budd-Chiari syndrome | Hepatic vein thrombosis; hepatomegaly, ascites, abdominal pain; diagnosed on Doppler USS or CT venography | Can cause abnormal LFTs with hepatomegaly |
When PBC progresses to cause frank jaundice, or when a patient presents with jaundice and cholestatic LFTs, you must exclude extrahepatic biliary obstruction [1][4][6]. This is the "surgical vs medical jaundice" question.
Types of jaundice [6]:
- Pre-hepatic: Haemolysis (spherocytosis, G6PD deficiency, malaria, sickle cell anaemia) [6]
- Hepatic: hepatitis, cirrhosis, intrahepatic cholestasis, medications, Gilbert's syndrome [6]
- Post-hepatic: obstructive jaundice [6]
Extrahepatic (post-hepatic) causes to exclude [4]:
| Location | Benign Causes | Malignant Causes |
|---|---|---|
| Intraluminal | Choledocholithiasis (CBD stones), recurrent pyogenic cholangitis (RPC), blood clot, parasites | Tumour fragments in CBD |
| Mural | Benign strictures (iatrogenic, TB, autoimmune), PSC | Cholangiocarcinoma (especially Klatskin tumour at hilum) [7] |
| Extramural | Chronic pancreatitis, pancreatic pseudocyst, Mirizzi syndrome | Carcinoma of head of pancreas, periampullary carcinoma, gallbladder carcinoma, hilar lymphadenopathy [4] |
Stone vs Tumour — Classic Exam Distinction
When facing obstructive jaundice, always differentiate stone from tumour [5]:
| Feature | Stone | Tumour |
|---|---|---|
| Jaundice | Intermittent (stone may pass) | Progressive |
| Pain | Painful (stone impaction at ampulla) | Painless (until advanced) |
| Fever | More likely (bile stasis → infection) | Less likely until late |
| Constitutional symptoms | Absent | LOW, LOA, night sweats |
| Courvoisier's sign | Negative (chronic fibrosed GB) | Positive (dilated GB) |
Painless progressive obstructive jaundice in elderly is malignant biliary obstruction until proven otherwise [5].
This is the classic symptomatic PBC presentation. The DDx here is narrower but still important:
| Condition | Key Distinguishing Features |
|---|---|
| PBC | AMA+, ↑ALP, middle-aged woman, autoimmune associations |
| PSC | AMA−, pANCA+, male, UC association, beaded ducts on MRCP |
| Drug-induced cholestasis | Drug history; resolves on withdrawal |
| Intrahepatic cholestasis of pregnancy | 3rd trimester; resolves post-partum; raised bile acids |
| Cholestasis of sepsis | Acutely unwell; infection source identified |
| Pruritus of chronic kidney disease | Uraemic pruritus; raised urea/creatinine; no cholestasis |
| Dermatological causes of pruritus | No cholestatic LFTs; skin lesion present (eczema, scabies, etc.) |
| Lymphoma (Hodgkin's) | B-symptoms; lymphadenopathy; pruritus without cholestasis |
This is the highest-yield differential for exams. These three autoimmune liver diseases frequently overlap and must be distinguished:
| Feature | PBC | PSC [3] | AIH | PBC-AIH Overlap |
|---|---|---|---|---|
| Sex | F > > > M (9:1) | M > F (7:3) | F > M (4:1) | F > > M |
| Age | 30–65 | 30–40 | Any age (bimodal: young + perimenopause) | 30–65 |
| Target | Small intrahepatic ducts | Large intra/extrahepatic ducts | Hepatocytes (interface hepatitis) | Both ducts + hepatocytes |
| LFT pattern | Cholestatic (↑ALP) | Cholestatic (↑ALP) | Hepatitic (↑ALT/AST > 5× ULN) | Mixed |
| AMA | +ve (95%) [1] | Negative | Negative | Positive |
| ANA | +ve (70%) — multiple nuclear dots, rim-like pattern [1] | Variable | +ve (common) | Positive |
| SMA | Negative | Negative | +ve (common) | Variable |
| pANCA | Negative | +ve (30–80%) [3] | Variable | Variable |
| IgM | ↑↑ | ↑ | Normal | ↑ |
| IgG | Normal/mild ↑ | Normal | ↑↑ | ↑ |
| Cholangiography | Normal | Beading (strictures + dilatation) | Normal | Normal or beading |
| Histology | Granulomatous duct destruction | Onion-skin periductal fibrosis | Interface hepatitis, plasma cells | Features of both |
| Disease association | Sjögren's, thyroid, scleroderma | UC (majority of PSC patients) [3] | Other autoimmune diseases | Autoimmune spectrum |
| Treatment | UDCA ± OCA | UDCA (limited evidence); transplant | Steroids + azathioprine | UDCA + steroids ± azathioprine |
| Cancer risk | HCC (if cirrhosis) | Cholangiocarcinoma [3] | HCC (if cirrhosis) | Both |
PBC-AIH Overlap — Don't Miss It
About 10% of PBC patients have concomitant features of AIH. Presence of ANA in PBC can cause confusion with autoimmune hepatitis or overlap syndrome (PBC plus autoimmune hepatitis) [1]. Suspect overlap when:
- A PBC patient has disproportionately elevated transaminases (ALT > 5× ULN)
- Interface hepatitis is seen on biopsy
- IgG is elevated (not just IgM)
This matters because overlap patients may need immunosuppression in addition to UDCA. Liver biopsy is indicated in patients if the diagnosis is in doubt or patient has evidence of autoimmune hepatitis [1].
The following flowchart illustrates the systematic approach to narrowing the DDx when PBC is suspected:
Physical Examination findings in obstructive jaundice to guide DDx [6]:
| Finding | Significance |
|---|---|
| Jaundice | Present in both intrahepatic and extrahepatic causes [6] |
| Stigmata of chronic liver disease | Points toward chronic hepatic cause (PBC cirrhosis, alcoholic liver disease, viral hepatitis) [6] |
| Pruritus (excoriations) | Cholestasis — any cause [6] |
| Courvoisier's law — palpable gallbladder in painless jaundice | Points towards malignant biliary obstruction (distal CBD/pancreatic head) rather than gallstones [6][4] — fibrosed GB from chronic cholelithiasis cannot distend |
| Troisier's sign (Virchow's node) | Left supraclavicular lymphadenopathy → metastatic GI malignancy [6] |
| Hepatomegaly | Many causes: PBC (progressive), HCC, metastatic disease, heart failure [6] |
| Sister Mary Joseph nodule | Periumbilical nodule → peritoneal metastasis from intra-abdominal malignancy [6] |
| Ascites | Peritoneal metastasis or decompensated cirrhosis [6] |
| Hyperpigmentation | Relatively specific to PBC (melanin deposition) |
| Xanthelasma/xanthomata | Cholestatic hyperlipidaemia — characteristic of PBC |
| Kayser-Fleischer rings | Wilson's disease (copper deposition in Descemet's membrane) — but note PBC can rarely cause copper retention too |
Courvoisier's Law — The Full Story
"In painless jaundice if the gallbladder is palpable, it is unlikely to be due to gallstones" [4] — this points towards malignant biliary obstruction. Why?
- Gallstones develop chronically → chronic cholecystitis → fibrosed, contracted gallbladder → cannot distend even if CBD is obstructed
- Malignant obstruction develops acutely → back-pressure dilates a previously normal gallbladder → palpable
Exceptions [4]:
- Double stones (one in CBD, one in cystic duct causing mucocele)
- RPC (pathology in bile duct, not GB → GB not fibrosed → can distend)
In Hong Kong specifically, certain diagnoses are more or less likely [2][4][5]:
| More Common in HK | Less Common in HK | Notes |
|---|---|---|
| Chronic HBV → cirrhosis → HCC | PSC (rare in Asia) | HBV is the dominant cause of cirrhosis in HK (~90%) [4] |
| Recurrent pyogenic cholangitis (RPC) — "Hong Kong disease" | Alcoholic liver disease (less than Western) | RPC associated with Clonorchis sinensis, intrahepatic pigment stones [5] |
| Cholangiocarcinoma (especially with RPC) | Aflatoxin-related HCC (not HK) | RPC is a risk factor for cholangioCA |
| Drug-induced liver injury (traditional Chinese medicine) | — | Important to ask about TCM use in HK patients |
PBC itself is uncommon in HK compared to Western populations but is increasingly diagnosed. When a middle-aged woman in HK presents with cholestatic LFTs and no biliary obstruction on USS, PBC should still be high on the differential — check AMA.
When you suspect PBC, you are really asking three questions:
- Is there extrahepatic obstruction? → USS ± MRCP to exclude stones, strictures, tumours
- Is this a different intrahepatic cholestatic disease? → Check AMA (PBC), pANCA/MRCP (PSC), IgG4 (IgG4-SC), drug history
- Is there overlap with AIH? → Check transaminases, IgG, consider biopsy if mixed picture
High Yield Summary — DDx of PBC
The differential diagnosis of PBC centres on excluding other causes of cholestasis:
-
Exclude extrahepatic obstruction FIRST — USS/MRCP to rule out stones (choledocholithiasis, RPC), strictures (PSC, cholangioCA), and masses (CA pancreas, periampullary CA)
-
Key intrahepatic DDx: PSC (male, UC, pANCA+, beaded ducts), AIH (↑ALT, ANA/SMA+, ↑IgG, interface hepatitis), drug-induced cholestasis, IgG4-SC, sarcoidosis
-
PBC-AIH overlap (~10%): disproportionately raised transaminases + interface hepatitis in a patient with AMA+ cholestasis → needs combined treatment
-
AMA-negative PBC (~5%): look for PBC-specific ANA patterns (anti-sp100, anti-gp210)
-
In HK: always consider HBV-related disease, RPC, and cholangioCA in the differential of cholestatic liver disease
-
Physical signs that help differentiate: Courvoisier's sign (malignant obstruction), Virchow's node/Sister Joseph nodule (metastatic GI malignancy), hyperpigmentation + xanthelasma (PBC-specific) [6]
Active Recall - Differential Diagnosis of PBC
References
[1] Senior notes: felixlai.md (Primary Biliary Cholangitis section, pages 532–539) [2] Senior notes: maxim.md (Hepatocellular carcinoma section — PBC as risk factor; Acute cholangitis — PBC as cause of strictures) [3] Senior notes: felixlai.md (Primary Sclerosing Cholangitis section, pages 529–532) [4] Senior notes: felixlai.md (Biliary Obstruction section, pages 499–501; Liver Cirrhosis section, pages 440–442) [5] Senior notes: maxim.md (Obstructive Jaundice section; Recurrent Pyogenic Cholangitis section; Jaundice DDx table — stone vs tumour) [6] Lecture slides: Malignant biliary obstruction.pdf (p2: Types of jaundice; p6: Physical Examination) [7] Senior notes: felixlai.md (Cholangiocarcinoma section, pages 548–549)
Diagnostic Criteria for Primary Biliary Cholangitis
Before memorising criteria, understand the reasoning behind them. PBC is an autoimmune disease that destroys small intrahepatic bile ducts. You cannot see these ducts on imaging (they're microscopic, < 100 µm). So the diagnosis rests on three pillars:
- Biochemistry — Is there evidence of cholestasis? (↑ ALP)
- Serology — Is there the autoimmune signature? (AMA)
- Histology — Can we see the duct destruction directly? (Liver biopsy)
And critically, you must first exclude anything else that could explain the cholestasis — especially extrahepatic biliary obstruction and other liver diseases.
Diagnosis of PBC is established if there is no extrahepatic biliary obstruction, no comorbidity affecting the liver, and ≥ 2 of the following 3 criteria are present [1]:
| Criterion | Detail | Rationale |
|---|---|---|
| 1. Cholestatic biochemistry | ALP ≥ 1.5× upper limit of normal [1] | ALP ("alkaline phosphatase") is an enzyme concentrated on the canalicular membrane of bile duct epithelium. When bile ducts are damaged/obstructed, ALP is released into blood. A persistently elevated ALP of hepatic origin (confirmed by concurrent ↑GGT) is the biochemical hallmark of cholestasis. The 1.5× threshold distinguishes clinically significant cholestasis from non-specific mild elevations. |
| 2. Serology | Presence of AMA at a titre of ≥ 1:40 [1] | AMA targets PDC-E2 on the inner mitochondrial membrane. AMA is ~95% sensitive and ~98% specific for PBC. AMA M2 is particularly diagnostic [1] — the M2 subtype specifically recognises the lipoyl domain of PDC-E2. |
| 3. Histology | Histological evidence of PBC: non-suppurative destructive cholangitis and destruction of interlobular bile ducts [1] | Direct visualisation of the hallmark "florid duct lesion" — lymphocytic and granulomatous inflammation centred on portal tract bile ducts, with epithelial damage and duct loss. "Non-suppurative" means there are NO neutrophils or pus (distinguishing it from ascending bacterial cholangitis). |
Practical Application of Diagnostic Criteria
In practice, most PBC is diagnosed with just criterion 1 + criterion 2 (raised ALP + positive AMA). Liver biopsy is often NOT required to establish the diagnosis [1] when these two are concordant. This is a key exam point — don't reflexively order a biopsy on every PBC patient.
The diagnosis requires meeting 2 out of 3 criteria, PLUS:
- No extrahepatic biliary obstruction (excluded by USS ± MRCP)
- No other comorbidity affecting the liver (excluded by history, viral serology, drug history, etc.)
| Scenario | Why It's Not Enough | What to Do |
|---|---|---|
| Raised ALP alone | Non-specific — could be bone disease, drug-induced, pregnancy, malignancy, extrahepatic obstruction | Confirm hepatic origin with GGT; check AMA; exclude obstruction with USS |
| AMA positive alone | ~0.5% of normal population are AMA+; AMA can be found in other autoimmune diseases | AMA alone without cholestatic biochemistry or histological evidence is insufficient — may represent "pre-clinical PBC" (these patients should be monitored as ~15–20% develop PBC within 5 years) |
| Biopsy showing duct destruction alone | Could be drug-induced ductopenia, sarcoidosis, graft-vs-host disease | Needs AMA or persistent ALP elevation to confirm PBC specifically |
Special Diagnostic Scenarios
About 5% of patients have classic PBC clinically and histologically but are AMA-negative. In these patients:
- Check for PBC-specific ANA patterns [1]:
- Multiple nuclear dots pattern (anti-sp100 antibodies)
- Rim-like / membranous pattern (anti-gp210 antibodies)
- These ANA patterns have high specificity for PBC
- Liver biopsy becomes essential in AMA-negative suspected PBC to confirm histological features [1]
- The disease behaves identically to AMA-positive PBC
Liver biopsy is indicated in patients if the diagnosis is in doubt, patient has evidence of autoimmune hepatitis, or if patient is not responding optimally with ursodeoxycholic acid [1].
Features suggesting overlap [1]:
- ALT > 5× ULN
- IgG > 2× ULN or positive anti-SMA
- Interface hepatitis on biopsy (moderate to severe)
The Paris criteria for PBC-AIH overlap require ≥ 2 of 3 PBC features AND ≥ 2 of 3 AIH features:
| PBC Features (need ≥ 2) | AIH Features (need ≥ 2) |
|---|---|
| ALP ≥ 2× ULN or GGT ≥ 5× ULN | ALT ≥ 5× ULN |
| AMA positive | IgG ≥ 2× ULN or anti-SMA positive |
| Florid duct lesion on biopsy | Moderate-to-severe interface hepatitis on biopsy |
ANA in PBC — A Prognostic, Not Just Diagnostic, Marker
Presence of ANA in PBC can cause confusion with autoimmune hepatitis or overlap syndrome [1]. But ANA positivity in PBC also carries prognostic significance: Presence of ANA is associated with more rapid progression of disease and a poorer prognosis [1]. So when you see ANA+ in a PBC patient, think:
- Could this be overlap with AIH? → Check ALT, IgG, consider biopsy
- This patient may have a worse prognosis regardless → Monitor more closely
The following algorithm represents the systematic approach from initial suspicion to confirmed diagnosis:
The Three-Step Diagnostic Logic
Think of PBC diagnosis in three simple steps:
- Is it cholestasis? → ↑ALP/GGT (yes) vs ↑ALT/AST predominantly (no — think hepatitic causes)
- Is it intrahepatic or extrahepatic? → USS shows normal bile ducts (intrahepatic) vs dilated ducts (extrahepatic)
- Is it PBC specifically? → AMA positive (yes, with high specificity) → diagnosis confirmed
Diagnosis of PBC is suspected when LFT shows a cholestatic pattern (↑ ALP and GGT) and USG shows no evidence of biliary disease or a SOL [1].
Investigation Modalities — Detailed Breakdown
1. Biochemical Tests
| Parameter | Expected Finding in PBC | Interpretation & Mechanism |
|---|---|---|
| ALP | Almost always elevated, often to striking levels, and is of hepatic origin [1] | ALP sits on the canalicular membrane of cholangiocytes and hepatocytes. Cholestasis causes detergent action of retained bile acids on cell membranes → ALP released into serum. It is the single most characteristic biochemical abnormality in PBC. Confirm hepatic origin by concurrent GGT elevation (bone ALP rises without GGT). |
| GGT | Elevated [1] | GGT (gamma-glutamyl transferase) is found on biliary epithelium. Elevation parallels ALP in cholestatic disease. Also induced by alcohol and certain drugs (enzyme inducer). In PBC, ↑GGT confirms the ↑ALP is of hepatobiliary rather than bone origin. |
| AST and ALT | Normal or slightly elevated [1] | Aminotransferases reflect hepatocyte injury. In PBC, the primary target is bile ducts, NOT hepatocytes (at least early on). So ALT/AST are only mildly raised. If ALT > 5× ULN → think PBC-AIH overlap. Serum aminotransferases may be normal or slightly elevated [1]. |
| Bilirubin | Normal in the early course of disease but becomes elevated as the disease progresses [1] | Early PBC → enough remaining bile ducts to handle bilirubin excretion → normal bilirubin. As ductopenia progresses → bilirubin cannot be excreted → rises. Conjugated and unconjugated bilirubin are both increased [1]. Elevated serum bilirubin is a poor prognostic sign [1] — it reflects severe, late-stage ductopenia. |
| Albumin | Hypoalbuminaemia in patients who have developed liver cirrhosis [1] | Albumin is synthesised by hepatocytes. In early PBC, hepatocyte function is preserved → normal albumin. In cirrhosis → synthetic failure → ↓albumin. Albumin half-life is ~20 days, so it reflects chronic (not acute) synthetic function. |
The LFT Pattern Tells the Story
PBC gives a cholestatic LFT pattern: ALP and GGT are disproportionately elevated compared to transaminases. This immediately separates it from hepatitic causes (viral hepatitis, AIH, Wilson's) where ALT/AST dominate. Think of it this way:
- Cholestatic pattern (↑↑ALP/GGT, ↔/↑ALT) → duct disease → PBC, PSC, drug-induced cholestasis, obstruction
- Hepatitic pattern (↑↑ALT/AST, ↔/↑ALP) → hepatocyte disease → viral, AIH, drug-induced hepatitis, Wilson's
- In cirrhosis from PBC, ALP is typically elevated but < 2–3× ULN due to late-stage ductopenia (fewer ducts = less ALP to release) [8]
CBC with differentials [1]:
- Pancytopenia [1] in advanced disease — reflects hypersplenism from portal hypertension
- Patients with PBC may have iron deficiency anaemia due to GI blood loss related to portal hypertension [1] — oesophageal or rectal variceal bleeding
- Patients with liver cirrhosis may develop leukopenia and thrombocytopenia [1] — sequestration in enlarged spleen + decreased thrombopoietin production by diseased liver
Serum lipids may be strikingly elevated in PBC [1]:
- Patients with early PBC often have mild elevations in LDL and VLDL and striking elevations in HDL [1]
- Why? Bile is the major route for cholesterol excretion. Cholestasis → cholesterol retention. Additionally, lipoprotein-X (Lp-X) — an abnormal lipoprotein — accumulates in cholestasis and is measured as "LDL" by some assays, artefactually inflating it.
- Increase in HDL explains why patients with PBC despite with striking hypercholesterolaemia do not appear to be at increased risk of death from atherosclerosis [1]
- Clinical pearl: Don't reflexively start statins for high cholesterol in PBC — the lipid profile is not atherogenic.
- PT / INR may be prolonged in two settings:
- Early — Vitamin K malabsorption from cholestasis → reduced synthesis of factors II, VII, IX, X (correctable with parenteral vitamin K)
- Late — Hepatic synthetic failure in cirrhosis → reduced production of ALL clotting factors (NOT correctable with vitamin K alone)
- Differentiating these two: give 10 mg IV vitamin K. If PT corrects → malabsorption. If PT does NOT correct → synthetic failure.
| Immunoglobulin | Finding | Significance |
|---|---|---|
| IgM | ↑↑ (Polyclonal) | Characteristically elevated in PBC — possibly reflects chronic B-cell stimulation against mitochondrial antigens. This is fairly specific: ↑IgM + cholestasis strongly suggests PBC. |
| IgG | Normal to mild ↑ | If IgG is markedly elevated (> 2× ULN), consider AIH or PBC-AIH overlap |
| IgG4 | Normal | If elevated, consider IgG4-associated cholangitis — important DDx |
2. Serological / Autoantibody Tests
Serological hallmark of PBC — 95% of patients are positive for AMA [1].
| Aspect | Detail |
|---|---|
| Target antigen | PDC-E2 (E2 subunit of pyruvate dehydrogenase complex) on inner mitochondrial membrane |
| Sensitivity | ~95% (5% of PBC is AMA-negative) |
| Specificity | ~98% (very few false positives) |
| Diagnostic subtype | AMA M2 is particularly diagnostic [1] — targets the lipoyl domain of PDC-E2 specifically |
| Other AMA subtypes | M4 (sulfite oxidase), M8 (outer mitochondrial membrane), M9 (glycogen phosphorylase) — less commonly tested; their presence may indicate more aggressive disease |
| Testing method | Indirect immunofluorescence (IIF) on HEp-2 cells or rat kidney substrate; confirmed by ELISA for M2 |
| False negatives | ~5% of true PBC — these are "AMA-negative PBC" patients; check PBC-specific ANA |
| AMA in non-PBC | AMA can rarely be positive in autoimmune hepatitis, drug-induced liver disease, or healthy individuals at low titre |
AMA — What 'M2' Actually Means
The "M" in AMA stands for "mitochondrial," and the number refers to different mitochondrial antigen subtypes identified by immunofluorescence patterns. M2 is the most clinically relevant because it targets PDC-E2, the actual autoantigen in PBC. When an exam question says "AMA-M2 positive," this is essentially pathognomonic for PBC.
Occurs in 70% of patients [1].
- Two immunofluorescence patterns are considered PBC-specific [1]:
- Multiple nuclear dots pattern — targeting anti-sp100 (a nuclear body protein)
- Rim-like or membranous pattern — targeting anti-gp210 (a nuclear pore glycoprotein)
- These patterns are distinct from the homogeneous or speckled ANA patterns seen in AIH or SLE
- Presence of ANA can cause confusion with autoimmune hepatitis or overlap syndrome [1]
- Presence of ANA is associated with more rapid progression of disease and a poorer prognosis [1]
- Anti-gp210 specifically is associated with hepatic failure phenotype (progressive jaundice)
- Anti-sp100 is more specific for PBC but has lower sensitivity
| Antibody | Purpose | Expected in PBC |
|---|---|---|
| Anti-smooth muscle antibody (SMA) | Exclude AIH / overlap | Usually negative in PBC; positive suggests AIH component |
| Anti-LKM (liver-kidney microsomal) | Exclude AIH type 2 | Negative in PBC |
| pANCA | Exclude PSC | pANCA is typically negative in PBC; positive in PSC (30–80%) [3] |
| Serum IgG4 | Exclude IgG4-associated cholangitis | Normal in PBC; elevated in IgG4-SC |
3. Radiological Tests
USG abdomen — imaging to exclude extrahepatic biliary obstruction or space-occupying lesion in the liver [1].
| Finding | Interpretation |
|---|---|
| Normal bile ducts (CBD < 6 mm, < 8 mm post-cholecystectomy) | Excludes extrahepatic obstruction → supports intrahepatic cholestasis (PBC, PSC, drugs) |
| Dilated bile ducts (CBD > 8 mm) | Suggests extrahepatic obstruction → NOT PBC → proceed to MRCP or ERCP to identify cause [5] |
| No space-occupying lesion | Excludes HCC or metastases as cause of deranged LFTs |
| Hepatomegaly | May be seen in PBC; non-specific |
| Splenomegaly | Suggests portal hypertension from advanced fibrosis/cirrhosis |
| Ascites | Decompensated cirrhosis |
| Surface nodularity / coarse echotexture | Suggests established cirrhosis [8] |
The maxim notes describe the jaundice investigation flowchart [5]: cholestatic pattern on LFTs → abdominal USS → if bile ducts normal → "Intrahepatic cholestasis — PBC/PSC, Drugs → AMA, P-ANCA, MRCP, Liver biopsy" [5]. If bile ducts dilated → "Extrahepatic cholestasis → Visualise bile duct" [5].
Why USS First?
USS is non-invasive, cheap, widely available, and answers the single most important question: Are the bile ducts dilated? If yes → extrahepatic obstruction (stones, tumour, stricture). If no → intrahepatic cause. This one finding pivots your entire diagnostic pathway. In PBC, bile ducts are always normal on USS because the disease targets microscopic ducts invisible to ultrasound.
MRCP — imaging to exclude extrahepatic biliary obstruction [1].
| Role | Detail |
|---|---|
| Primary purpose in PBC workup | Exclude extrahepatic causes when USS is equivocal, or to definitively rule out PSC |
| Expected finding in PBC | Normal biliary tree — because PBC affects small ducts (< 100 µm) that are below MRCP resolution |
| Expected finding in PSC | Characteristic multifocal strictures that alternate with dilatation of intrahepatic or extrahepatic bile ducts resulting in "beaded" appearance [3] |
| Advantages | Non-invasive, no radiation, no contrast injection needed for biliary imaging, excellent at identifying duct anatomy |
| When to order | When USS cannot exclude obstruction; when PSC is in the differential; when AMA is negative and duct pathology must be excluded |
- NOT routinely indicated in PBC diagnosis — PBC is a small-duct disease; ERCP visualises large ducts
- Indicated in patients who are unable to undergo MRCP (e.g., implanted metal devices) or in patients with early PSC changes that may be missed by MRCP [3]
- ERCP carries procedural risks (pancreatitis, perforation, cholangitis) and should only be performed when therapeutic intervention (stone removal, stent placement) is anticipated
- Non-invasive assessment of liver fibrosis — measures liver stiffness using ultrasound-based shear wave velocity [8]
- Increasingly used to stage fibrosis in PBC without biopsy
- Liver stiffness values:
- < 7.1 kPa → minimal fibrosis (F0-F1)
- 7.1–9.5 kPa → significant fibrosis (F2)
- 9.5–12.5 kPa → advanced fibrosis (F3)
- > 12.5 kPa → cirrhosis (F4)
- Advantages: non-invasive, repeatable, good for monitoring progression
- Limitations: unreliable in obesity, ascites, acute hepatitis (inflammation falsely elevates stiffness)
4. Liver Biopsy
Liver biopsy is often NOT required to establish the diagnosis of PBC but can provide useful information with regard to staging and prognosis [1].
Indicated in patients if [1]:
- The diagnosis is in doubt (e.g., AMA-negative, atypical features)
- Patient has evidence of autoimmune hepatitis (elevated ALT/IgG → need to confirm/exclude overlap)
- Patient is not responding optimally with ursodeoxycholic acid (to reassess staging and look for other pathology)
- Need to assess fibrosis stage when non-invasive methods are inconclusive
Histological findings in PBC are staged on a scale of 0–4 [1]:
| Stage | Name | Key Histological Features | Clinical Correlate |
|---|---|---|---|
| Stage 0 | Normal | Normal liver architecture | Pre-clinical PBC (AMA+ only) |
| Stage 1 | Portal | Inflammation and/or abnormal connective tissue confined to portal areas [1]; Florid duct lesion: lymphocytic and epithelioid granulomatous inflammation centred on interlobular bile ducts; duct epithelial damage and focal duct destruction | Often asymptomatic; detected on screening LFTs |
| Stage 2 | Periportal | Inflammation and/or fibrosis confined to portal and periportal areas [1]; Ductular proliferation (reactive ductules); periportal hepatitis (interface hepatitis) | May develop early symptoms (pruritus, fatigue) |
| Stage 3 | Septal | Bridging fibrosis [1] — fibrous septa linking portal tracts to each other or to central veins; progressive ductopenia (loss of bile ducts in > 50% of portal tracts) | More symptomatic; early features of portal hypertension |
| Stage 4 | Cirrhosis | Cirrhosis [1] — regenerative nodules, complete architectural distortion, severe ductopenia | Decompensated liver disease; jaundice, ascites, varices |
The hallmark lesion — the "florid duct lesion" — is pathognomonic:
- A medium-sized interlobular bile duct is surrounded by a dense lymphocytic infiltrate
- Epithelioid granulomata may be seen around the damaged duct
- The duct epithelium shows degenerative changes (vacuolation, nuclear irregularity, eosinophilic change)
- "Non-suppurative" = NO neutrophils (this is immune-mediated destruction, not infection)
The Florid Duct Lesion vs Onion-Skin Fibrosis
Don't confuse the histology of PBC with PSC:
- PBC: Florid duct lesion — granulomatous inflammation destroying small interlobular ducts. "Non-suppurative destructive cholangitis."
- PSC: Onion-skin periductal fibrosis — concentric layers of fibrosis around medium/large bile ducts. Very different pattern.
Both cause ductopenia eventually, but the mechanism and morphology differ completely.
Once PBC is diagnosed, additional tests are needed to assess disease complications and associated conditions:
| Investigation | Purpose | Rationale |
|---|---|---|
| Thyroid function tests | Screen for Hashimoto's thyroiditis | Associated in 10–15% [1]; check at diagnosis and periodically |
| Schirmer's test / salivary flow | Screen for Sjögren's syndrome | Associated in 40–65% [1]; ask about sicca symptoms |
| DEXA scan | Screen for osteoporosis | Hepatic osteodystrophy — retained toxins inhibit osteoblasts + vitamin D malabsorption [1] |
| Serum vitamin A and calcidiol | Screen for fat-soluble vitamin deficiency | Vitamin A and D deficiency are more common requiring supplementation; measurement of serum vitamin A and calcidiol is required [1] |
| Serum vitamin K (or PT/INR) | Screen for vitamin K deficiency | Coagulopathy from malabsorption |
| Serum AFP + USS 6-monthly | HCC surveillance (if cirrhotic) | Patients with PBC and cirrhosis are at increased risk of HCC [1] |
| Upper GI endoscopy (OGD) | Variceal screening (if cirrhotic) | Portal hypertension → oesophageal varices → risk of UGIB |
| FibroScan or ELF score | Non-invasive fibrosis staging | Monitor progression; assess need for transplant referral |
Factors associated with a poorer prognosis [1]:
| Factor | Explanation |
|---|---|
| Unresponsive to ursodeoxycholic acid (UDCA) | UDCA responders have near-normal life expectancy; non-responders progress to cirrhosis. Assessed at 1 year using criteria (see below). |
| Presence of symptoms at the time of diagnosis | Symptomatic patients have more advanced disease at baseline |
| Elevated ALP and bilirubin levels | Reflect severe cholestasis and ductopenia; bilirubin is the single strongest prognostic marker |
| Advanced histological stage | Stage 3–4 at diagnosis = already significant fibrosis/cirrhosis |
| Presence of anti-nuclear antibodies (ANA) | Associated with more rapid progression [1]; anti-gp210 particularly predicts hepatic failure |
Assessing UDCA Response (at 12 months)
Multiple criteria exist to define "UDCA response" — all assess whether the biochemistry has improved after 1 year of UDCA:
| Criteria | Definition of Response |
|---|---|
| Barcelona criteria | ALP decrease > 40% of baseline OR normalisation |
| Paris-I criteria | ALP < 3× ULN AND AST < 2× ULN AND bilirubin ≤ 1 mg/dL |
| Paris-II criteria (early disease) | ALP < 1.5× ULN AND AST < 1.5× ULN AND normal bilirubin |
| Toronto criteria | ALP < 1.67× ULN |
| UK-PBC risk score | Composite score using ALP, ALT/AST, bilirubin, albumin, platelet count at 12 months |
| GLOBE score | Uses age at diagnosis + bilirubin, ALP, albumin, platelet count after 1 year UDCA |
Non-responders require second-line therapy (obeticholic acid, bezafibrate) or transplant referral.
| Investigation | Key Finding in PBC | When to Order |
|---|---|---|
| LFT | ↑↑ALP/GGT; ↔/↑ALT/AST; ↔/↑bilirubin (late) | Always — first-line |
| AMA | Positive ≥ 1:40 (95%); M2 subtype diagnostic | Always — diagnostic |
| ANA | Positive 70%; look for nuclear dots or rim pattern | Always — prognostic and for DDx of overlap |
| Immunoglobulins | ↑IgM; normal IgG (↑IgG → overlap) | Always |
| USS abdomen | Normal bile ducts; no SOL | Always — exclude extrahepatic obstruction |
| MRCP | Normal in PBC; beading in PSC | If USS equivocal or PSC suspected |
| Liver biopsy | Florid duct lesion; staging 0–4 | Only if diagnosis in doubt, AIH suspected, or suboptimal UDCA response |
| FibroScan | Liver stiffness correlates with fibrosis stage | Non-invasive staging and monitoring |
| Lipid profile | ↑↑Cholesterol (↑HDL, Lp-X) | Baseline; reassurance — NOT atherogenic |
| CBC | Pancytopenia in advanced disease | Baseline and monitoring |
| TFTs | Hypothyroidism (Hashimoto's) | Screen at diagnosis |
| Vitamin A, 25-OH-D | Deficiency from fat malabsorption | Screen at diagnosis |
| DEXA | Osteoporosis/osteopenia | Screen at diagnosis |
| AFP + USS 6-monthly | HCC surveillance | If cirrhosis established |
High Yield Summary — Diagnosis of PBC
-
Diagnostic criteria: ≥ 2 of 3 — ALP ≥ 1.5× ULN, AMA ≥ 1:40, histological evidence — PLUS no extrahepatic obstruction [1]
-
In practice: Most diagnosed by raised ALP + positive AMA alone. Biopsy often NOT required [1].
-
AMA-M2 is the serological hallmark (~95% sensitive, ~98% specific). In the 5% who are AMA-negative, look for PBC-specific ANA (anti-sp100, anti-gp210).
-
USS is mandatory to exclude extrahepatic obstruction. Normal ducts + ↑ALP + AMA+ = PBC.
-
Biopsy indications: diagnostic doubt, suspected AIH overlap, suboptimal UDCA response.
-
Bilirubin is the strongest prognostic marker — rising bilirubin = advanced ductopenia = poor prognosis.
-
Always screen for: thyroid disease, Sjögren's, osteoporosis, fat-soluble vitamin deficiency, and HCC (if cirrhotic).
-
UDCA response at 12 months determines prognosis and need for second-line therapy.
Active Recall - Diagnostic Criteria, Algorithm and Investigations for PBC
[1] Senior notes: felixlai.md (Primary Biliary Cholangitis section, pages 532–539) [3] Senior notes: felixlai.md (Primary Sclerosing Cholangitis section, pages 529–532) [5] Senior notes: maxim.md (Obstructive Jaundice section — jaundice investigation flowchart; intrahepatic vs extrahepatic cholestasis algorithm) [8] Senior notes: felixlai.md (Liver Cirrhosis — Diagnosis section, pages 442–446)
Management of Primary Biliary Cholangitis
Before diving into individual treatments, understand the management framework. PBC is a chronic autoimmune disease that destroys bile ducts. You cannot regenerate destroyed bile ducts. So the management strategy is:
- Slow/halt disease progression — UDCA and second-line agents to protect remaining ducts and reduce cholestatic injury
- Manage symptoms — pruritus, fatigue, sicca symptoms
- Prevent and treat complications — fat-soluble vitamin deficiency, osteoporosis, portal hypertension
- Replace the liver when it fails — liver transplantation as definitive treatment for end-stage disease
The good news: with UDCA, patients who respond biochemically have a near-normal life expectancy. The challenge: ~40% do not adequately respond to UDCA and need escalation.
1. Disease-Modifying Therapy
Ursodeoxycholic acid (UDCA) is the cornerstone and 1st line therapy in treatment of PBC [1].
Let's break down the name: "urso-" = bear (originally isolated from bear bile — Ursus species), "deoxy-" = removal of an oxygen/hydroxyl group, "cholic acid" = bile acid. UDCA is a naturally occurring hydrophilic bile acid that constitutes only ~3% of the normal human bile acid pool.
| Aspect | Detail |
|---|---|
| Dosage | 13–15 mg/kg/day [1], given orally, usually in divided doses (or single daily dose) |
| Duration | Should be continued indefinitely once started [1] — this is a lifelong therapy; it is the only treatment aimed at modifying the natural history of the disease [1] |
| Mechanism of action | Affects biliary composition and flow by an unknown mechanism [1]. However, several mechanisms are now understood: |
Mechanisms of UDCA — explained from first principles:
The problem in PBC is that toxic hydrophobic bile acids (chenodeoxycholic acid, lithocholic acid) accumulate in the liver due to cholestasis → these damage hepatocyte membranes and bile duct epithelium → worsen inflammation and fibrosis.
UDCA works by:
-
Displacing toxic bile acids — UDCA is hydrophilic ("water-loving"). When you flood the bile acid pool with UDCA (it becomes ~40–60% of the pool), it displaces hydrophobic toxic bile acids → reduced hepatocyte injury. Think of it as diluting poison with a harmless substance.
-
Choleretic effect — UDCA stimulates bicarbonate secretion by cholangiocytes (the "bicarbonate umbrella") → protects bile duct epithelium from bile acid toxicity → slows duct destruction.
-
Anti-apoptotic — UDCA inhibits mitochondrial membrane permeabilisation → reduces hepatocyte apoptosis triggered by toxic bile acids.
-
Immunomodulatory — UDCA reduces aberrant HLA class I expression on hepatocytes, reducing immune-mediated attack. It also decreases production of pro-inflammatory cytokines (IL-2, IL-4, IFN-γ).
-
Stimulates biliary secretion — Enhances canalicular transporter expression (BSEP, MRP2) → promotes bile acid excretion → reduces intracellular bile acid toxicity.
Clinical significance [1]:
- Decreases pruritus and improves LFT (bilirubin/ALP/GGT) [1]
- Increases survival, delays progression to end-stage liver disease and delays liver transplantation [1]
- UDCA responders have survival rates comparable to the age- and sex-matched general population
- Does NOT reverse established cirrhosis — it slows progression and may reverse early fibrosis
Adverse effects [1]:
- GI upset is the most common including abdominal pain and diarrhoea [1]
- Weight gain (~3 kg in first year)
- Very rarely: hair thinning
- Overall, UDCA is remarkably well-tolerated
Contraindications:
- Complete biliary obstruction (bile acid cannot reach the bile duct if there's complete blockage)
- Known hypersensitivity to UDCA or bile acids
- Caution in patients with calcified gallstones (theoretical risk of stone dissolution → complications, though this is more relevant to gallstone dissolution therapy)
UDCA — The Exam Must-Know
Q3 from the case study: "Is there any specific drug treatment for PBC and how effective is it?" The answer is UDCA [1]:
- Affects biliary composition and flow by unknown mechanism
- Results: Decreases pruritus, Improves liver function, Improves survival and delays liver transplantation [1]
The key exam point: UDCA is the ONLY disease-modifying therapy with proven survival benefit. It must be continued indefinitely. Response is assessed at 12 months.
After 12 months of UDCA at adequate dose, you must assess whether the patient has responded. This is THE critical management decision in PBC — it determines prognosis and need for second-line therapy.
| Criteria | Definition of Adequate Response | Notes |
|---|---|---|
| Barcelona | ALP decrease > 40% of baseline OR normalisation | Simple; widely used |
| Paris-I | ALP < 3× ULN AND AST < 2× ULN AND Bilirubin ≤ 1 mg/dL | For advanced disease |
| Paris-II | ALP < 1.5× ULN AND AST < 1.5× ULN AND normal bilirubin | For early disease |
| Toronto | ALP < 1.67× ULN | Simplest single-parameter criterion |
| GLOBE score | Composite: age + ALP + bilirubin + albumin + platelets at 12 months | Validated; predicts transplant-free survival |
| UK-PBC score | Composite: ALP + ALT/AST + bilirubin + albumin + platelets at 12 months | Most widely recommended in current guidelines (2024 EASL) |
Why assess at 12 months? UDCA takes time to reach steady-state effect on the bile acid pool and cholangiocyte protection. Assessing too early leads to false non-response.
What proportion respond? Approximately 60% of PBC patients show adequate biochemical response to UDCA. The remaining ~40% are "inadequate responders" who need escalation.
Obeticholic acid — indicated in patients with an inadequate response to UDCA defined as ALP level > 2× upper limit of normal after 1 year of UDCA [1].
Let's break down the name: "obe-" = from obese/bile acid research, "ti-" = modification, "cholic acid" = bile acid. OCA is a semi-synthetic derivative of chenodeoxycholic acid, modified to be a potent FXR agonist.
| Aspect | Detail |
|---|---|
| Mechanism | Farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor in hepatocytes and cholangiocytes that acts as a "bile acid sensor." When activated: (1) ↓ bile acid synthesis (via repression of CYP7A1), (2) ↑ bile acid export (via BSEP upregulation), (3) ↓ bile acid uptake (via NTCP downregulation), (4) anti-fibrotic and anti-inflammatory effects. Net result: reduced intrahepatic bile acid concentration → less cholestatic injury. |
| Dosage | Start 5 mg/day; titrate to 10 mg/day after 3 months if tolerated and ALP/bilirubin not normalised |
| Indication | Add-on to UDCA in inadequate responders; or monotherapy if UDCA-intolerant |
| Clinical benefit | Significant reduction in ALP and bilirubin; long-term outcome data less robust than UDCA |
| Key adverse effect | Pruritus — dose-dependent, often severe, affects ~70% of patients. This is ironic: you're treating a disease that causes pruritus with a drug that worsens pruritus. Mechanism: FXR activation in the ileum increases FGF19, which can promote pruritus. |
| Contraindications | Decompensated cirrhosis (Child-Pugh B or C) — OCA can worsen liver failure and has been associated with hepatic decompensation and death in cirrhotic patients. The FDA issued a black box warning in 2021 and OCA was withdrawn from the US market in 2024 for the PBC indication due to safety concerns in advanced disease, though it remains available in some jurisdictions under restricted use. |
| Monitoring | LFTs every 3 months; discontinue if signs of hepatic decompensation |
OCA Safety Concerns — Important Update
In June 2024, the FDA requested withdrawal of OCA (Ocaliva) from the US market for PBC after a confirmatory trial failed to demonstrate clinical benefit and showed a concerning safety signal in advanced disease. However, OCA remains available in some countries (including potentially via special access in HK) and may still appear in exam questions. The key point: OCA is contraindicated in decompensated cirrhosis and must be used with caution. Current guidelines now favour bezafibrate or elafibranor as preferred second-line options.
Bezafibrate and fenofibrate are PPARα agonists that have shown significant benefit in PBC:
| Aspect | Bezafibrate | Fenofibrate |
|---|---|---|
| Mechanism | PPARα agonist → (1) ↓ bile acid synthesis, (2) ↓ inflammation (NF-κB inhibition), (3) ↑ phospholipid secretion (protects biliary epithelium), (4) stimulates MDR3 transporter → enhanced biliary phospholipid secretion | Similar PPARα mechanism |
| Dosage | 400 mg/day (modified-release) | 200 mg/day (micronised) |
| Evidence | BEZURSO trial (2018) — significant improvement in ALP, bilirubin, pruritus, and composite endpoint; included in EASL 2024 guidelines as second-line | Smaller trials; less robust evidence than bezafibrate |
| Key advantage | May actually improve pruritus (unlike OCA which worsens it) | |
| Adverse effects | Myalgia, rhabdomyolysis (rare), hepatotoxicity (monitor LFTs), renal impairment | Similar; more hepatotoxic than bezafibrate |
| Contraindications | Severe renal impairment (eGFR < 30), decompensated cirrhosis, concurrent statin use increases myopathy risk | Same as bezafibrate |
Elafibranor ("ela" = selective, "fibr" = fibrate-like, "anor" = novel modulator) is a dual PPARα/δ agonist approved by the FDA in June 2024 for PBC patients with inadequate UDCA response.
| Aspect | Detail |
|---|---|
| Mechanism | Dual PPARα/δ agonist. PPARα activation → ↓ bile acid synthesis and inflammation (like fibrates). PPARδ activation → ↑ cholesterol efflux, anti-inflammatory effects in macrophages, improved insulin sensitivity. The dual action provides broader anti-cholestatic and anti-fibrotic effects. |
| Dosage | 80 mg orally once daily |
| Evidence | ELATIVE trial (2023) — significant ALP normalisation and bilirubin improvement vs placebo |
| Indication | Add-on to UDCA in inadequate responders; or monotherapy if UDCA-intolerant |
| Advantage over OCA | Better tolerated; does NOT worsen pruritus; no hepatotoxicity signal |
| Adverse effects | Nausea, diarrhoea, abdominal pain (mild); weight increase |
| Contraindications | Decompensated cirrhosis; pregnancy/lactation |
Seladelpar was approved by the FDA in August 2024 — a selective PPARδ agonist:
- 10 mg orally once daily
- ENHANCE trial showed significant biochemical response
- Well tolerated; may improve pruritus
- Now included in updated AASLD guidelines as second-line option
The Evolving Treatment Landscape — 2024-2026
The PBC treatment landscape has changed dramatically since the reference notes were written. The current hierarchy (EASL 2024, AASLD 2024):
First-line: UDCA 13–15 mg/kg/day (unchanged)
Second-line (if inadequate UDCA response at 12 months):
- Preferred: Bezafibrate 400 mg/day (strongest evidence + improves pruritus)
- Alternative: Elafibranor 80 mg/day or Seladelpar 10 mg/day (newly approved PPARα/δ or PPARδ agonists)
- Less preferred: OCA (safety concerns; restricted availability)
Third-line / refractory: Liver transplantation
| Step | Treatment | When | Key Points |
|---|---|---|---|
| 1st line | UDCA 13–15 mg/kg/day [1] | At diagnosis; continue indefinitely | Only proven survival benefit; well tolerated |
| 2nd line | Bezafibrate 400 mg/day OR Elafibranor 80 mg/day OR Seladelpar 10 mg/day | Inadequate UDCA response at 12 months | Add to UDCA (not replace it) |
| 2nd line (alternative) | Obeticholic acid 5–10 mg/day [1] | Inadequate UDCA response | Worsens pruritus; contraindicated in decompensated cirrhosis; restricted availability post-2024 |
| PBC-AIH overlap | UDCA + Prednisolone ± Azathioprine | If overlap confirmed by Paris criteria | Immunosuppression needed for the AIH component |
| End-stage | Liver transplantation | Decompensated cirrhosis, intractable symptoms, HCC | Definitive; excellent outcomes; PBC can recur post-transplant (~20%) |
2. Symptom Management
Pruritus is often the most debilitating symptom and can be present even before jaundice develops. Management follows a stepladder approach [1]:
Step 1: Cholestyramine (First-line for pruritus)
Cholestyramine [1]:
- Pharmacological category: Resins [1] (bile acid sequestrant)
- Mechanism: ↑ Excretion of bile acids in jejunum and ileum by chelating bile salts [1]. Cholestyramine is a positively-charged anion-exchange resin that binds negatively-charged bile acids in the intestinal lumen → prevents their enterohepatic recirculation → reduces serum bile acid levels → less pruritogen delivery to skin. Think of it as a "bile acid sponge" in the gut.
- Dosage: 4 g before and after breakfast (timing matters: give 4 hours apart from UDCA because cholestyramine will also bind UDCA and reduce its absorption)
- Adverse effects include dyspepsia, bloating, diarrhoea and constipation [1]
- Also reduces absorption of fat-soluble vitamins (A, D, E, K) — supplement as needed
- Can interfere with absorption of other medications (thyroid hormones, warfarin, digoxin) — take other drugs 1 hour before or 4–6 hours after cholestyramine
Cholestyramine — Timing Is Everything
A critical practical point: cholestyramine binds UDCA in the gut and neutralises it. Always separate dosing by at least 4 hours. Give cholestyramine before breakfast, UDCA at lunchtime/evening. If you don't separate them, you're sabotaging your disease-modifying therapy.
Step 2: Rifampicin (Second-line for pruritus)
Rifampicin [1]:
- Category: Enzyme-inducing antibiotic [1]
- Mechanism: Improves pruritus in cholestasis [1] through multiple mechanisms:
- Induces hepatic microsomal enzymes (CYP3A4, CYP2C) → enhanced metabolism and detoxification of pruritogens
- Activates PXR (pregnane X receptor) → upregulates bile acid export pumps (MRP2) → enhanced biliary excretion of pruritogens
- May reduce serum autotaxin activity (the enzyme producing lysophosphatidic acid, a key pruritogen)
- Dosage: 150–300 mg/day (start low)
- Potentially hepatotoxic [1] — monitor LFTs every 2–4 weeks for the first 3 months; discontinue if transaminases rise significantly
- Also causes orange discolouration of urine, tears, sweat (warn patients)
- Drug interactions: potent CYP inducer → reduces efficacy of many drugs (OCP, warfarin, immunosuppressants)
Step 3: Opioid Antagonists (Third-line for pruritus)
Naloxone/Naltrexone/Nalmefene [1]:
- Opioid antagonists [1]
- Mechanism: Cholestatic pruritus involves upregulation of endogenous opioid tone. Bile acids stimulate opioid receptor pathways → itch. Opioid antagonists block μ-opioid receptors → reduce itch signal transmission.
- Naloxone is given IV whereas naltrexone and nalmefene are given orally [1]
- Dosage: Naltrexone 25–50 mg/day orally (start at 12.5 mg to avoid opioid withdrawal-like reaction)
- Side effects: Initial opioid withdrawal-like syndrome (nausea, anxiety, dysphoria) — start at very low dose and titrate slowly; also potential hepatotoxicity
- Not first-line because of withdrawal reaction and limited efficacy data
Step 4: IBAT Inhibitors / Other Agents (Fourth-line)
- Linerixibat / Maralixibat — ileal bile acid transporter (IBAT) inhibitors. Block bile acid reabsorption in terminal ileum → increased faecal bile acid excretion → reduced enterohepatic circulation → less pruritogen load. Linerixibat showed benefit in the GLIMMER trial (2023).
- Sertraline (SSRI) — 75–100 mg/day; may modulate serotonergic itch pathways; modest evidence
- UV-B phototherapy — unclear mechanism; may alter cutaneous nerve fibres
- Plasmapheresis / albumin dialysis (MARS) — for severe refractory pruritus as bridge to transplant
- Nasobiliary drainage — temporary measure to physically divert bile in extreme cases
Step 5: Liver Transplantation (Definitive for intractable pruritus)
When pruritus is so severe that quality of life is unacceptable despite all medical therapy, this alone can be an indication for transplant listing.
| Step | Agent | Mechanism | Key Considerations |
|---|---|---|---|
| 1 | Cholestyramine | Bile acid sequestrant | Separate from UDCA by 4 hours; GI side effects |
| 2 | Rifampicin | Enzyme induction; PXR activation | Hepatotoxic — monitor LFTs; drug interactions |
| 3 | Naltrexone | Opioid antagonist | Withdrawal reaction; start low |
| 4 | Linerixibat | IBAT inhibitor | Newer; diarrhoea; emerging evidence |
| 5 | Liver transplant | Definitive | For truly intractable pruritus |
Fatigue in PBC is multifactorial and unfortunately does NOT correlate with disease severity and often does NOT improve after transplantation:
- Exclude and treat contributing causes: anaemia, hypothyroidism (check TFTs), depression, sleep disturbance from pruritus, adrenal insufficiency
- No specific effective treatment for PBC-related fatigue
- Supportive measures: regular exercise (shown to improve fatigue and quality of life), sleep hygiene, psychological support
- Modafinil has been trialled with limited benefit
From associated Sjögren's syndrome (40–65%):
- Artificial tears (preservative-free) for dry eyes
- Pilocarpine (muscarinic agonist) — stimulates residual salivary gland function
- Saliva substitutes (methylcellulose-based) for dry mouth
- Regular dental check-ups (dry mouth → increased caries risk)
- Avoid anticholinergic medications (worsen dryness)
Medium chain triglycerides (MCT) [1]:
- Symptomatic steatorrhoea due to bile acid insufficiency can be partially corrected by restricting dietary fat [1]
- MCTs are added or used for cooking if caloric supplementation is required to maintain body weight [1]
- MCT does not require bile acids for absorption to enterocytes and hence can be digested and absorbed into circulation despite low bile acid concentration [1]
- MCT is absorbed by diffusion and does not require micellar formation [1]
Why does this work from first principles?
- Normal dietary fats are long-chain triglycerides (LCTs, C14–C20) → require bile acid-dependent micellar solubilisation → absorbed via lymphatics → chylomicrons
- MCTs (C6–C12 fatty acids) are smaller → directly absorbed across enterocyte membrane by passive diffusion → enter portal circulation directly (NOT lymphatics)
- So when bile acids are deficient (as in PBC cholestasis), MCTs bypass the impaired step entirely
Vitamin supplementation [1]:
- Vitamin A — oral supplement to compensate for deficiency [1]
- Vitamin D — prescribed to treat the hepatic osteodystrophy [1]
- Vitamin A and D deficiency are more common requiring supplementation [1]
- Measurement of serum vitamin A and calcidiol is required [1]
- Vitamin K — oral or parenteral if coagulopathy present (check PT/INR)
- Vitamin E — supplement if neurological symptoms or very low levels
| Vitamin | Deficiency Consequence | Supplement | Monitoring |
|---|---|---|---|
| A | Night blindness, xerophthalmia | 25,000–50,000 IU orally 2–3 times/week | Serum retinol levels |
| D | Osteomalacia, contributes to osteoporosis | Cholecalciferol 800–2000 IU/day (or higher if deficient) | Serum 25-OH-vitamin D (calcidiol) |
| E | Peripheral neuropathy, ataxia (rare) | 100–400 IU/day | Serum α-tocopherol |
| K | Coagulopathy (↑ PT/INR) | 10 mg orally or 10 mg IV if severe | PT/INR |
Hepatic osteodystrophy (Osteopenia/Osteoporosis/Osteomalacia) [1]:
- Metabolic bone disease includes osteopenia and osteoporosis or rarely osteomalacia [1]
- Characteristic bone disorder in PBC reflects the inhibitory effect of a retained toxin on the osteoblast which prevents it from functioning normally [1]
Treatment [1]:
- Calcium and vitamin D supplementation [1] — 1000–1200 mg calcium + 800–2000 IU vitamin D daily
- Bisphosphonates [1] — Example: Alendronate [1]
- Mechanism: bisphosphonates ("bis" = two, "phosphonate" = phosphorus-containing) bind to hydroxyapatite in bone → taken up by osteoclasts → inhibit farnesyl pyrophosphate synthase (in the mevalonate pathway) → osteoclast apoptosis → reduced bone resorption
- Indicated when T-score ≤ −2.5 (osteoporosis) or ≤ −1.5 with additional risk factors
- Concern in PBC: oesophageal varices are a relative contraindication to oral bisphosphonates (risk of oesophageal ulceration) → use IV zoledronic acid instead if varices present
- Regular weight-bearing exercise
- DEXA scan every 2–3 years to monitor
Osteoporosis in PBC — A Double Hit
PBC causes osteoporosis through two mechanisms:
- Vitamin D malabsorption → less calcium absorption → osteomalacia
- Direct osteoblast inhibition by retained cholestatic toxins (bilirubin, bile acids) → reduced bone formation → osteoporosis
This is why you treat with BOTH vitamin D (for the malabsorption) AND bisphosphonates (for the osteoblast inhibition). Calcium + vitamin D alone is insufficient if T-score shows osteoporosis.
Hyperlipidaemia [1]:
- Increased cholesterol level in PBC does not increase atherosclerotic risk [1]
- Majority are elevation of HDL and lipoprotein-X which are anti-atherogenic [1]
- Treatment is not always needed and is indicated only if familial or other known risk factors are present [1]
Practical approach:
- Do NOT routinely start statins for elevated cholesterol in PBC
- If patient has additional cardiovascular risk factors (family history, diabetes, smoking, hypertension) → treat per standard lipid guidelines
- If statin indicated, use with caution (cholestasis can alter statin metabolism)
Liver transplantation — indicated in patients with [1]:
- Serum bilirubin > 6 mg/dL [1] (reflects severe ductopenia with very poor prognosis)
- Decompensated liver cirrhosis [1]
- Anticipated death within a year due to [1]:
- Intractable pruritus unresponsive to all medical therapy (quality of life indication)
| Aspect | Detail |
|---|---|
| Timing | Refer when MELD score ≥ 15 or MELD-Na ≥ 15; earlier if intractable symptoms |
| Outcomes | Excellent — 5-year survival ~80–85%; among the best outcomes for any liver transplant indication |
| PBC recurrence post-transplant | ~20–30% develop histological recurrence in the graft (usually mild, responds to UDCA); graft loss from recurrence is rare (~5% at 10 years) |
| Type of transplant | Deceased donor liver transplant (DDLT) preferred; living donor liver transplant (LDLT) in regions with organ shortage (relevant to HK — LDLT is more commonly performed at Queen Mary Hospital) |
| Post-transplant management | Standard immunosuppression (tacrolimus-based) + resume UDCA (to prevent/treat recurrence) + monitor AMA (may persist but does not predict recurrence) |
The Case Study Revisited
The case in the senior notes [1] illustrates transplant timing perfectly: 50-year-old woman → diagnosed PBC → started UDCA (daily oral medication which was followed by some improvement of her liver function and pruritus [1]) → progressive ascites → hepatic encephalopathy → referred for liver transplantation assessment [1]. This patient has decompensated cirrhosis with ascites requiring paracentesis and encephalopathy — clear transplant indications.
7. Management of Complications of Cirrhosis in PBC
When PBC progresses to cirrhosis, management of complications is the same as for cirrhosis of any cause:
- First-line: Sodium restriction (< 2 g/day = < 88 mmol/day) + Spironolactone (100–400 mg/day) ± Furosemide (40–160 mg/day)
- Refractory: Large-volume paracentesis (LVP) with albumin replacement (6–8 g albumin per litre drained), TIPS
- Mechanism: Portal hypertension → splanchnic vasodilation → reduced effective arterial blood volume → RAAS activation → sodium and water retention → ascites
Hepatic encephalopathy management [1]:
- IV Dextrose drip — provide adequate calorie intake to prevent protein breakdown [1]
- Oral Lactulose — as an enema with the aim of inducing bowel movements 2–4 times per day [1]
- No protein diet [1] (short-term; long-term moderate protein restriction 1–1.5 g/kg/day is preferred over complete restriction)
- Any treatable precipitating factor should be identified and treated [1]
Lactulose mechanism [1]:
- Non-absorbable disaccharide [1]
- Acts as an osmotic diarrheal agent [1]
- Acted upon by lactobacilli in colon to form H₂ and CO₂ [1]
- Acidic pH buffers NH₃ from gut-derived bacteria and in blood to form NH₄⁺ [1]
- NH₃ (ammonia) is lipophilic and crosses the blood-brain barrier → neurotoxic
- NH₄⁺ (ammonium) is charged/hydrophilic and CANNOT cross → trapped in gut lumen → excreted in faeces
- Side effects: Flatulence, dehydration (from excessive diarrhoea), aversion to sweet taste [1]
Rifaximin (non-absorbable antibiotic) is added for secondary prophylaxis of encephalopathy.
Precipitating factors for hepatic encephalopathy [1]:
- ↑ Protein intake [1]
- GI bleeding (↑ protein from blood in gut + ↓ liver blood supply) [1]
- Constipation [1]
- Infection (especially spontaneous bacterial peritonitis) [1]
- Over-diuresis (dehydration and electrolyte disturbance) [1]
- Inappropriate paracentesis without adequate albumin infusion [1]
- Shunting procedures including TIPS [1]
- Drugs — hypnotics [1]
- Primary prophylaxis: Non-selective beta-blockers (propranolol, carvedilol) or endoscopic band ligation
- Acute bleeding: Resuscitation → IV terlipressin + antibiotics → emergency OGD with band ligation → TIPS if refractory
- Secondary prophylaxis: Band ligation + non-selective beta-blocker
Patients with PBC and cirrhosis are at increased risk of HCC [1]:
- AFP + USS every 6 months
- CT/MRI if suspicious lesion identified
| Management Domain | Intervention | Key Details |
|---|---|---|
| Disease-modifying (1st line) | UDCA 13–15 mg/kg/day | Lifelong; assess response at 12 months; proven survival benefit |
| Disease-modifying (2nd line) | Bezafibrate 400 mg/day or Elafibranor 80 mg/day or Seladelpar 10 mg/day or OCA 5–10 mg/day | Add to UDCA; OCA contraindicated in decompensated cirrhosis |
| PBC-AIH overlap | UDCA + Prednisolone ± Azathioprine | Immunosuppression for AIH component |
| Pruritus | Cholestyramine → Rifampicin → Naltrexone → IBAT inhibitor | Stepwise; separate cholestyramine from UDCA by 4 hours |
| Dietary | MCT for steatorrhoea; Vitamin A, D, (E, K) supplementation | MCT does not require bile acids for absorption |
| Bone disease | Calcium + Vitamin D + Alendronate | IV bisphosphonate if varices present |
| Hyperlipidaemia | Usually no treatment needed | Not atherogenic (↑HDL, Lp-X) |
| Fatigue | Supportive; exercise; exclude secondary causes | No specific effective therapy |
| Sicca | Artificial tears; pilocarpine; saliva substitutes | Sjögren's association |
| Cirrhosis complications | Standard management (ascites, encephalopathy, varices, HCC) | As for cirrhosis of any aetiology |
| Definitive | Liver transplantation | Bilirubin > 6, decompensated CLD, intractable pruritus, HCC |
High Yield Summary — Management of PBC
-
UDCA is THE first-line treatment: 13–15 mg/kg/day, continued indefinitely. It is the only treatment that modifies the natural history of PBC, with proven survival benefit [1].
-
Assess response at 12 months: ~60% respond adequately. Non-responders need second-line therapy.
-
Second-line: Bezafibrate (PPARα agonist, 400 mg/day) is now preferred; elafibranor and seladelpar are newly approved PPARδ agonists. OCA [1] is an option but has safety concerns (worsens pruritus, contraindicated in decompensated cirrhosis).
-
Pruritus management is stepwise: Cholestyramine (bile acid sequestrant, separate from UDCA) → Rifampicin (enzyme inducer, hepatotoxic) → Naltrexone (opioid antagonist) → IBAT inhibitors → transplant [1].
-
Nutritional support: MCTs for steatorrhoea (bypass bile acid-dependent absorption); Vitamins A and D supplementation (most commonly deficient) [1].
-
Bone disease: Calcium + Vitamin D + Bisphosphonates (alendronate) [1].
-
Liver transplantation: Indicated for bilirubin > 6 mg/dL, decompensated cirrhosis, intractable symptoms, HCC. Excellent outcomes (~85% 5-year survival). PBC can recur in graft (~20%) [1].
-
Hepatic encephalopathy: Lactulose (trap ammonia as NH₄⁺ in gut), dextrose (prevent catabolism), identify and treat precipitants [1].
Active Recall - Management of PBC
References
[1] Senior notes: felixlai.md (Primary Biliary Cholangitis — Treatment section, pages 535–539; Case study and Q&A, pages 538–540) [3] Senior notes: felixlai.md (Primary Sclerosing Cholangitis — Treatment section, pages 531–532) [8] Senior notes: felixlai.md (Liver Cirrhosis section — causes, complications, pages 440–446)
Complications of Primary Biliary Cholangitis
Complications of PBC fall into two categories, exactly as the exam expects you to present them [1]:
- General complications of cirrhosis — these occur once PBC has progressed to Stage 4 (cirrhosis) and are identical to complications of cirrhosis from any aetiology
- Specific complications of PBC — unique to the cholestatic and autoimmune nature of PBC itself, and can occur before cirrhosis develops
Understanding this distinction is important because it tells you when to expect each complication and how to monitor for it. A patient with early PBC (Stage 1–2) may have severe pruritus and fat-soluble vitamin deficiency but will NOT have ascites or varices. A patient with PBC cirrhosis (Stage 4) can have ALL complications.
Part A: General Complications of Cirrhosis
These occur when PBC progresses to Stage 4 (cirrhosis) [1]. The pathophysiology is the same as cirrhosis from any cause — the key driver is architectural distortion of the liver causing increased intrahepatic vascular resistance → portal hypertension → a cascade of downstream consequences, combined with hepatocellular failure → reduced synthetic and metabolic function.
1. Portal Hypertension
Portal hypertension is the haemodynamic consequence of cirrhosis and is the root cause of most cirrhotic complications.
Why does PBC cause portal hypertension?
- Progressive fibrosis → regenerative nodules compress sinusoids and hepatic venules → increased intrahepatic vascular resistance
- Activated hepatic stellate cells contract around sinusoids → further increases resistance
- Portal pressure gradient > 5 mmHg = portal hypertension; > 10 mmHg = clinically significant (varices form); > 12 mmHg = variceal bleeding risk
Abdominal distension from ascites [1]
- Pathophysiology: Portal hypertension → splanchnic vasodilation (NO-mediated) → reduced effective arterial blood volume → RAAS activation + ADH secretion → sodium and water retention → fluid transudation into peritoneal cavity. Simultaneously, hypoalbuminaemia (reduced hepatic synthesis) reduces plasma oncotic pressure → further fluid shift.
- Clinical correlation: The case study patient had progressive abdominal swelling, which was only partially controlled by diuretics [1], requiring repeated hospital admission for paracentesis [1] — this represents refractory ascites, a transplant indication.
- Complications of ascites: Spontaneous bacterial peritonitis (SBP), abdominal discomfort, respiratory compromise, umbilical hernia
- Management: Sodium restriction, spironolactone ± furosemide, large-volume paracentesis with albumin replacement, TIPS for refractory cases, transplant
Haematemesis from oesophageal variceal bleeding [1]
- Pathophysiology: Portal hypertension → blood seeks alternative routes to bypass the liver → portosystemic collaterals develop at sites of portal-systemic anastomosis:
- Oesophageal/gastric varices (left gastric vein → oesophageal veins → azygos system)
- Rectal varices (superior rectal → middle/inferior rectal veins)
- Caput medusae (recanalised umbilical vein → epigastric veins)
- Retroperitoneal collaterals
- Oesophageal varices are thin-walled and under high pressure → rupture → massive UGIB → haematemesis and/or melaena
- Mortality: 15–20% per bleeding episode, even with modern treatment
- Surveillance: OGD screening when cirrhosis diagnosed; repeat 1–3 yearly
- Management: Non-selective beta-blockers (propranolol/carvedilol) for primary prophylaxis; endoscopic band ligation + terlipressin for acute bleeding; TIPS if refractory
- Pathophysiology: Portal hypertension → congestion of splenic vein → splenic engorgement → splenomegaly → excessive sequestration and destruction of blood cells in the enlarged spleen → pancytopenia (thrombocytopenia most prominent, then leukopenia, then anaemia)
- Reduced thrombopoietin production by the diseased liver also contributes to thrombocytopenia
Confusion from hepatic encephalopathy [1]
Pathophysiology: Two mechanisms work in concert:
- Hepatocellular failure → liver cannot metabolise ammonia (via urea cycle) → hyperammonaemia
- Portosystemic shunting → gut-derived toxins (ammonia, mercaptans, short-chain fatty acids, GABA-like substances) bypass the liver entirely via collaterals → reach the systemic circulation and cross the blood-brain barrier
Ammonia (NH₃) is lipophilic → crosses BBB → converted to glutamine by astrocytes → osmotic astrocyte swelling → cerebral oedema → impaired neurotransmission
Clinical features [1]:
- Drowsy to comatose [1]
- Flapping tremor (asterixis) [1] — caused by sudden involuntary loss of muscle tone during sustained posture; reflects impaired motor neuron function from neurotoxins
- Fetor hepaticus [1] — sweet, musty odour on breath from dimethyl sulphide, a mercaptan that is normally metabolised by the liver
- Constructional apraxia, day-night reversal, personality change (early)
Grading (West Haven criteria):
- Grade 0: Subclinical (detectable only on psychometric testing)
- Grade 1: Mild confusion, altered sleep
- Grade 2: Drowsy, inappropriate behaviour, asterixis
- Grade 3: Somnolent but arousable, gross disorientation
- Grade 4: Coma
Precipitating factors [1]:
- ↑ Protein intake [1]
- GI bleeding [1] — provides a massive protein (haemoglobin) load to the gut
- Constipation [1] — prolongs ammonia absorption from gut
- Infection (especially SBP) [1]
- Over-diuresis [1] — hypovolaemia, hypokalaemia, metabolic alkalosis (alkalotic pH favours NH₃ over NH₄⁺ → more ammonia crosses BBB)
- Inappropriate paracentesis without adequate albumin infusion [1]
- Shunting procedures including TIPS [1]
- Drugs — hypnotics [1]
The case study illustrates this perfectly: the patient became drowsy after celebrating her daughter's marriage [1] — likely precipitated by increased protein intake at the celebration → diagnosed with "liver coma" [1] → managed with low protein diet and laxatives (lactulose) [1].
Management [1]:
- IV Dextrose drip — provide adequate calorie intake to prevent protein breakdown [1]
- Oral Lactulose — inducing bowel movements 2–4 times per day [1]
- Lactulose mechanism: Non-absorbable disaccharide → osmotic laxative → acidifies colonic pH → converts NH₃ to NH₄⁺ (trapped, non-absorbable) → faecal excretion [1]
- Rifaximin (non-absorbable antibiotic) — reduces ammonia-producing gut bacteria; used for secondary prophylaxis
- Identify and treat precipitating factor [1]
- Pathophysiology: Advanced cirrhosis → severe splanchnic vasodilation → arterial underfilling → intense renal vasoconstriction (RAAS, sympathetic nervous system, ADH) → functional renal failure with structurally normal kidneys
- Type 1 (HRS-AKI): Rapid deterioration (doubling of creatinine in < 2 weeks); often triggered by SBP; very poor prognosis without transplant
- Type 2 (HRS-CKD): Slower progression; associated with refractory ascites
- Management: IV albumin + terlipressin (splanchnic vasoconstrictor → reverses the underfilling); definitive treatment is transplant
- Pathophysiology: The liver synthesises virtually ALL coagulation factors (except vWF, which is endothelial, and factor VIII). In cirrhosis:
- Reduced synthesis of factors II, V, VII, IX, X, fibrinogen
- Reduced synthesis of natural anticoagulants (protein C, protein S, antithrombin) — so cirrhosis is actually a rebalanced haemostatic state, not simply "anticoagulated"
- Vitamin K malabsorption (from cholestasis) further reduces factors II, VII, IX, X specifically
- Thrombocytopenia from hypersplenism
- Clinical manifestation: Easy bruising, prolonged PT/INR, increased bleeding risk from procedures
Patients with PBC and cirrhosis are at increased risk of HCC [1][2].
- Pathophysiology: Cirrhosis of any cause creates a pro-carcinogenic environment — chronic inflammation → regenerative nodules → dysplastic nodules → hepatocellular carcinoma. The cycle of cell death, inflammation, and regeneration → accumulation of somatic mutations → malignant transformation.
- PBC is listed as an autoimmune cause of cirrhosis leading to HCC, alongside AIH and PSC [2][9].
- Any cause of cirrhosis: infection (HBV, HCV), metabolic (ALD, NAFLD, Wilson's disease), immune (PBC, PSC) [2] can lead to HCC.
- Risk: Lower than HBV/HCV-related cirrhosis (~4% lifetime in PBC cirrhosis vs ~20–30% in HBV cirrhosis), but still significant enough to warrant surveillance
- Surveillance: AFP + USS every 6 months in all PBC patients with established cirrhosis
- HCC in PBC tends to present later in the disease course (only after cirrhosis is established), unlike HBV where HCC can occur without cirrhosis
HCC Risk in PBC — Don't Forget Surveillance
- Pathophysiology: Ascites provides a culture medium for bacteria. In cirrhosis, gut barrier function is impaired (portal hypertensive enteropathy) + immune dysfunction (reduced complement, opsonisation defects) → bacterial translocation from gut to ascitic fluid → SBP
- Organisms: Most commonly E. coli, Klebsiella, Streptococcus pneumoniae (monomicrobial)
- Diagnosis: Ascitic fluid PMN count ≥ 250/mm³
- Treatment: IV ceftriaxone or cefotaxime + IV albumin
- SBP is a precipitant of hepatic encephalopathy [1] and a transplant indication [1]
Part B: PBC-Specific Complications
These are complications that arise from the cholestatic nature of PBC itself and can occur at any stage, including before cirrhosis develops. They are unique to PBC (and other cholestatic diseases) rather than being generic cirrhotic complications.
Pruritus [1]
- Pathophysiology: Cholestasis → accumulation of pruritogens in blood and skin. The key mediators are now understood to include:
- Lysophosphatidic acid (LPA) — produced by the enzyme autotaxin (ATX); serum ATX levels correlate best with itch severity
- Bile acids — activate TGR5 receptors on cutaneous sensory nerve fibres → itch signalling
- Endogenous opioids — cholestasis upregulates opioidergic tone → opioid-mediated itch (explains why opioid antagonists help)
- Histamine — may play a minor role, but antihistamines are generally ineffective in cholestatic pruritus (this is NOT histamine-mediated itch)
- Clinical features: Worst at night, can precede jaundice by months to years, may be so severe as to cause excoriations and sleep deprivation → quality of life impairment that alone can justify transplant listing
- Management: Stepwise — cholestyramine → rifampicin → naltrexone → IBAT inhibitors → transplant (covered in detail in the Management section)
Pruritus Is Not Just a Symptom — It's a Complication
Pruritus in PBC deserves special emphasis because it can be the most debilitating aspect of the disease. Unlike pruritus from dermatological causes, cholestatic pruritus does NOT respond to antihistamines (because the mechanism involves autotaxin/LPA and opioid pathways, NOT histamine). Don't prescribe cetirizine and hope for the best — use the specific cholestatic itch ladder.
Steatorrhoea (malabsorption of dietary fat) and vitamin deficiency [1]
Pathophysiology — trace this from first principles:
- PBC destroys bile ducts → cholestasis → reduced bile acid secretion into duodenum
- Bile acids are essential for micellar solubilisation of dietary fat (long-chain triglycerides and fat-soluble vitamins)
- Without micelles → fat cannot be absorbed across the intestinal epithelium → steatorrhoea (pale, bulky, foul-smelling, floating stools)
- Fat-soluble vitamins (A, D, E, K) are co-absorbed with fat in micelles → malabsorption of all four fat-soluble vitamins
Lipid malabsorption — result of decreased biliary secretion of bile acids [1]
Fat-soluble vitamins A, D, E, K deficiency [1]:
- Vitamin A and D deficiency are more common requiring supplementation [1]
- Measurement of serum vitamin A and calcidiol is required [1]
| Vitamin | Consequence of Deficiency | Why This Vitamin Is Specifically Affected | Screening/Monitoring |
|---|---|---|---|
| A (Retinol) | Night blindness, xerophthalmia, immune dysfunction | Requires micelles for absorption; liver stores eventually depleted | Serum retinol |
| D (Cholecalciferol) | Osteomalacia (bone softening), contributes to osteoporosis, muscle weakness | Requires micelles; also liver hydroxylation (25-OH-D) may be impaired in advanced disease | Serum calcidiol (25-OH-vitamin D) [1] |
| E (α-Tocopherol) | Peripheral neuropathy, spinocerebellar ataxia, haemolytic anaemia (rare) | Requires micelles; body stores are limited | Serum α-tocopherol |
| K (Phylloquinone) | Coagulopathy — ↑ PT/INR, easy bruising, bleeding | Requires micelles; very limited body stores (days to weeks) | PT/INR; response to parenteral vitamin K |
Mnemonic — Fat-soluble vitamins: "A, D, E, K" — "A Dark, Empty Kitchen" (A = vision/dark adaptation, D = bones, E = nerves, K = Koagulation)
Hepatic osteodystrophy (Osteopenia/Osteoporosis/Osteomalacia) [1]
Metabolic bone disease includes osteopenia and osteoporosis or rarely osteomalacia [1]
Pathophysiology — this is a "double hit" mechanism:
-
Osteoporosis (reduced bone formation): Characteristic bone disorder in primary biliary cirrhosis which reflects the inhibitory effect of a retained toxin on the osteoblast which prevents it from functioning normally [1]. Retained bile acids, bilirubin, and other cholestatic toxins directly inhibit osteoblast activity → reduced bone formation → osteoporosis. This is the dominant mechanism in PBC.
-
Osteomalacia (defective mineralisation): Vitamin D malabsorption → reduced calcium absorption from gut → inadequate mineralisation of osteoid → soft bones. This is less common because most patients receive vitamin D supplementation, but it can occur if supplementation is inadequate.
Clinical consequences: Vertebral compression fractures, hip fractures, chronic bone pain, kyphosis Prevalence: Osteoporosis occurs in 20–45% of PBC patients; increases with disease duration Risk factors for worse bone disease: Post-menopausal women (oestrogen withdrawal + PBC effects = compounded risk), advanced cholestasis, low BMI, smoking, corticosteroid use (if overlap syndrome)
Management [1]:
Hyperlipidaemia [1]
Increased cholesterol level in PBC do not increase atherosclerotic risk [1]
Pathophysiology:
- Bile is the major excretory route for cholesterol. Cholestasis → impaired cholesterol excretion → accumulation in blood
- Additionally, lipoprotein metabolism is altered: increased HDL, appearance of lipoprotein-X (Lp-X) — an abnormal lipoprotein unique to cholestasis
- Lp-X is measured by some assays as "LDL" but is NOT atherogenic
- Majority are elevation of HDL and lipoprotein-X which are anti-atherogenic [1]
Clinical features: Xanthelasma (yellowish periorbital plaques), xanthomata (lipid deposits in tendons, skin creases), grossly elevated total cholesterol (sometimes > 15 mmol/L)
Treatment is not always needed and is indicated only if familial or other known risk factors are present [1]
Don't Panic About the Cholesterol!
Serum cholesterol in PBC can be spectacularly high — sometimes 15–20 mmol/L. Junior doctors often panic and start statins. But the lipid profile is NOT atherogenic — it's predominantly HDL and Lp-X. These patients do NOT have increased cardiovascular mortality. Only treat hyperlipidaemia if there are independent cardiovascular risk factors (family history, diabetes, smoking, hypertension) on top of PBC.
Biliary strictures — up to 60% of patients may develop a dominant stricture in intrahepatic or extrahepatic biliary tree [9]
- Pathophysiology: Chronic periductal inflammation and fibrosis → narrowing of bile ducts → stricture formation. Although PBC primarily affects small ducts, progressive disease can lead to fibrotic changes affecting larger ducts as well.
- Clinical significance: Strictures worsen cholestasis, predispose to stone formation and cholangitis, and can mimic malignant obstruction
- Management: MRCP to delineate anatomy; endoscopic dilatation/stenting if symptomatic; always exclude cholangiocarcinoma as the cause of a new dominant stricture
Choledocholithiasis and cholelithiasis — due to cholesterol or pigment stones [9]
- Pathophysiology:
- Cholesterol stones: Cholestasis alters bile composition → supersaturation of bile with cholesterol (reduced bile acid secretion tips the cholesterol saturation index)
- Pigment stones: Altered bilirubin metabolism in chronic liver disease → increased unconjugated bilirubin in bile → calcium bilirubinate precipitation
- Gallstones occur in ~30–40% of PBC patients (higher than general population)
- Can cause biliary colic, acute cholecystitis, or choledocholithiasis → obstructive jaundice (confusing the picture with worsening PBC cholestasis)
Cholangitis — develops spontaneously in patients with bile duct stones or obstructing strictures or in patients after undergoing endoscopic or surgical manipulation [9]
- Pathophysiology: Bile duct obstruction (from stones or strictures) → bile stasis → bacterial colonisation (ascending infection from duodenum) → acute cholangitis
- Clinical features: Charcot's triad (fever, RUQ pain, jaundice) or Reynolds' pentad (+ shock + confusion in suppurative cholangitis)
- Organisms: E. coli, Klebsiella, Enterococcus
- Management: IV antibiotics, biliary drainage (ERCP ± sphincterotomy for stone removal)
Cholangiocarcinoma — high incidence necessitates screening including USG or MRCP with a measurement of serum CA19-9 [9]
Gallbladder cancer [9]
- Pathophysiology: Chronic biliary inflammation → epithelial metaplasia → dysplasia → carcinoma. The same chronic inflammatory milieu that drives duct destruction in PBC also creates a pro-carcinogenic environment in the biliary epithelium.
- Risk: Lower than in PSC (where cholangiocarcinoma risk is 10–15% lifetime), but still elevated compared to general population
- Screening: Regular USS or MRCP + serum CA 19-9 (though CA 19-9 is non-specific and can be elevated in any cholestatic state)
- Suspect malignancy if: Sudden clinical deterioration, rapidly rising bilirubin disproportionate to disease stage, new dominant stricture, rapid weight loss
Cholangiocarcinoma — PBC vs PSC Risk
The risk of cholangiocarcinoma is much higher in PSC than PBC. However, PBC patients are NOT immune — screening is still recommended [9]. A sudden change in clinical trajectory in a stable PBC patient (especially worsening jaundice unresponsive to treatment, or a new stricture on imaging) should always prompt evaluation for cholangiocarcinoma.
Because PBC clusters with other autoimmune diseases, complications of these associations should also be considered:
| Associated Disease | Prevalence | Potential Complications |
|---|---|---|
| Sjögren's syndrome | 40–65% [1] | Keratoconjunctivitis sicca (corneal damage from dryness), dental caries (reduced saliva), parotid gland enlargement, rarely lymphoma (MALT lymphoma) |
| Hashimoto's thyroiditis | 10–15% [1] | Hypothyroidism → fatigue (compounding PBC fatigue), weight gain, constipation, cognitive slowing |
| Systemic sclerosis | 5–10% [1] | Raynaud's phenomenon, oesophageal dysmotility (GERD, dysphagia — important because GERD + oesophageal varices = increased bleeding risk), pulmonary fibrosis, renal crisis |
| Rheumatoid arthritis | 5–10% [1] | Joint destruction, extra-articular manifestations |
| Coeliac disease | ~6% | Exacerbates malabsorption; gluten-free diet needed |
| Renal tubular acidosis (Type 1) | Rare | Non-anion-gap metabolic acidosis; nephrocalcinosis; worsens osteoporosis (chronic acidosis mobilises bone calcium) |
Factors associated with a poorer prognosis [1]:
| Prognostic Factor | Explanation |
|---|---|
| Unresponsive to ursodeoxycholic acid (UDCA) [1] | UDCA responders have near-normal life expectancy; non-responders progress to cirrhosis and transplant need |
| Presence of symptoms at the time of diagnosis [1] | Symptomatic patients have more advanced disease at baseline and a shorter time to complications |
| Elevated ALP and bilirubin levels [1] | Reflect ongoing cholestatic injury; bilirubin is the single strongest prognostic marker — rising bilirubin = severe ductopenia |
| Advanced histological stage [1] | Stage 3–4 at diagnosis = already significant fibrosis/cirrhosis with limited time before decompensation |
| Presence of anti-nuclear antibodies (ANA) [1] | Associated with more rapid progression [1]; anti-gp210 particularly associated with hepatic failure phenotype |
Natural history without treatment: Median survival from symptom onset to death or transplant was ~10–15 years before UDCA era. With UDCA, responders have survival comparable to general population. Non-responders still face progressive disease, but newer second-line agents (bezafibrate, elafibranor, seladelpar) are improving outcomes.
| Category | Complication | Pathophysiological Mechanism | When It Occurs |
|---|---|---|---|
| Cirrhosis — Portal HT | Ascites | ↑Portal pressure + hypoalbuminaemia + RAAS activation | Stage 4 |
| Cirrhosis — Portal HT | Variceal bleeding | Portosystemic collaterals at oesophageal plexus | Stage 4 |
| Cirrhosis — Portal HT | Splenomegaly/hypersplenism | Splenic congestion → sequestration → pancytopenia | Stage 3–4 |
| Cirrhosis — Failure | Hepatic encephalopathy | Failed ammonia clearance + portosystemic shunting | Stage 4 |
| Cirrhosis — Failure | Hepatorenal syndrome | Splanchnic vasodilation → renal vasoconstriction → functional renal failure | Stage 4 |
| Cirrhosis — Failure | Coagulopathy | ↓Clotting factor synthesis + vitamin K malabsorption + thrombocytopenia | Stage 3–4 |
| Cirrhosis — Malignancy | HCC | Chronic inflammation → regeneration → dysplasia → carcinoma | Stage 4 |
| Cirrhosis — Infection | SBP | Gut bacterial translocation into ascites + immune dysfunction | Stage 4 |
| PBC-specific | Pruritus | Autotaxin/LPA + bile acids + endogenous opioids in skin | Any stage |
| PBC-specific | Steatorrhoea + vitamin deficiency | ↓Bile acid secretion → ↓micellar fat absorption → ↓fat-soluble vitamins | Any stage |
| PBC-specific | Hepatic osteodystrophy | Retained toxins inhibit osteoblasts + vitamin D malabsorption | Any stage, worsens with duration |
| PBC-specific | Hyperlipidaemia | ↓Cholesterol excretion in bile; ↑HDL + Lp-X (NOT atherogenic) | Any stage |
| PBC-specific | Biliary strictures | Periductal inflammation → fibrosis → narrowing | Progressive |
| PBC-specific | Gallstones | Altered bile composition → cholesterol/pigment stone formation | Any stage |
| PBC-specific | Cholangitis | Stones/strictures → bile stasis → ascending bacterial infection | Any stage |
| PBC-specific | Cholangiocarcinoma | Chronic biliary inflammation → epithelial metaplasia → carcinoma | Late; requires screening |
High Yield Summary — Complications of PBC
Complications are divided into two groups [1]:
A. General complications of cirrhosis (once Stage 4 reached):
- Portal hypertension → Ascites, variceal bleeding, splenomegaly/hypersplenism
- Hepatic encephalopathy — precipitated by protein load, GI bleed, infection, over-diuresis, constipation, drugs
- HCC — surveillance with AFP + USS 6-monthly in all cirrhotic PBC patients
- Hepatorenal syndrome, coagulopathy, SBP
B. PBC-specific complications (can occur at any stage):
- Pruritus — most debilitating symptom; mediated by autotaxin/LPA, bile acids, endogenous opioids; NOT histamine
- Steatorrhoea + fat-soluble vitamin deficiency (A, D, E, K) — from ↓bile acid secretion → ↓micellar absorption; A and D most commonly deficient
- Hepatic osteodystrophy — osteoporosis (retained toxins inhibit osteoblasts) > osteomalacia (vitamin D deficiency); treat with calcium, vitamin D, bisphosphonates
- Hyperlipidaemia — ↑HDL and lipoprotein-X; NOT atherogenic; usually no treatment needed
- Biliary strictures, cholelithiasis, cholangitis — from altered bile composition and periductal fibrosis
- Cholangiocarcinoma — risk lower than PSC but still elevated; screen with USG/MRCP + CA 19-9
Prognostic factors: UDCA non-response, symptomatic presentation, elevated bilirubin, advanced stage, ANA positivity [1]
Active Recall - Complications of PBC
References
[1] Senior notes: felixlai.md (Primary Biliary Cholangitis — Complications section, pages 536–540; Case study Q2-Q7, pages 538–540; Prognosis section, page 537) [2] Senior notes: maxim.md (Hepatocellular carcinoma — Risk factors section: PBC listed as immune cause of cirrhosis leading to HCC) [8] Senior notes: felixlai.md (Liver Cirrhosis — Overview, Etiology, Complications sections, pages 440–446) [9] Senior notes: felixlai.md (Primary Sclerosing Cholangitis — Complications section, pages 531–532; shared cholestatic complications listed under both PSC and PBC)
High Yield Summary
Primary Biliary Cholangitis (PBC) — Key Points for Exams:
-
Definition: Autoimmune T-cell mediated destruction of small intrahepatic interlobular bile ducts → cholestasis → fibrosis → cirrhosis.
-
Epidemiology: 90–95% female, age 30–65, less common in HK than in Western populations.
-
Autoantigen: PDC-E2 (pyruvate dehydrogenase complex E2 subunit) on inner mitochondrial membrane.
-
Serological hallmark: AMA (anti-mitochondrial antibody) positive in ~95%; AMA-M2 subtype is most specific.
-
Key associations: Sjögren's (40–65%) > Hashimoto's (10–15%) > Scleroderma (5–10%) > RA (5–10%).
-
Clinical presentation: 50–60% asymptomatic at diagnosis. When symptomatic: pruritus (most common, worse at night, precedes jaundice) and fatigue. Jaundice is a late and poor prognostic sign.
-
Physical signs: Excoriations, hyperpigmentation (melanin, NOT bilirubin), xanthomata, hepato-splenomegaly (late).
-
Histological staging: 0 (normal) → 1 (portal inflammation, florid duct lesion) → 2 (periportal) → 3 (bridging fibrosis) → 4 (cirrhosis).
-
Diagnostic criteria: ≥ 2 of: (a) ALP ≥ 1.5× ULN, (b) AMA ≥ 1:40, (c) Histological evidence. No extrahepatic biliary obstruction.
-
Complications: All complications of cirrhosis + specific: pruritus, steatorrhoea, fat-soluble vitamin deficiency, hepatic osteodystrophy, hyperlipidaemia, HCC risk.
-
PBC vs PSC: PBC = female, small ducts, AMA+, Sjögren's. PSC = male, large ducts, pANCA+, UC, cholangioCA risk.
High Yield Summary — DDx of PBC
The differential diagnosis of PBC centres on excluding other causes of cholestasis:
-
Exclude extrahepatic obstruction FIRST — USS/MRCP to rule out stones (choledocholithiasis, RPC), strictures (PSC, cholangioCA), and masses (CA pancreas, periampullary CA)
-
Key intrahepatic DDx: PSC (male, UC, pANCA+, beaded ducts), AIH (↑ALT, ANA/SMA+, ↑IgG, interface hepatitis), drug-induced cholestasis, IgG4-SC, sarcoidosis
-
PBC-AIH overlap (~10%): disproportionately raised transaminases + interface hepatitis in a patient with AMA+ cholestasis → needs combined treatment
-
AMA-negative PBC (~5%): look for PBC-specific ANA patterns (anti-sp100, anti-gp210)
-
In HK: always consider HBV-related disease, RPC, and cholangioCA in the differential of cholestatic liver disease
-
Physical signs that help differentiate: Courvoisier's sign (malignant obstruction), Virchow's node/Sister Joseph nodule (metastatic GI malignancy), hyperpigmentation + xanthelasma (PBC-specific) [6]
High Yield Summary — Diagnosis of PBC
-
Diagnostic criteria: ≥ 2 of 3 — ALP ≥ 1.5× ULN, AMA ≥ 1:40, histological evidence — PLUS no extrahepatic obstruction [1]
-
In practice: Most diagnosed by raised ALP + positive AMA alone. Biopsy often NOT required [1].
-
AMA-M2 is the serological hallmark (~95% sensitive, ~98% specific). In the 5% who are AMA-negative, look for PBC-specific ANA (anti-sp100, anti-gp210).
-
USS is mandatory to exclude extrahepatic obstruction. Normal ducts + ↑ALP + AMA+ = PBC.
-
Biopsy indications: diagnostic doubt, suspected AIH overlap, suboptimal UDCA response.
-
Bilirubin is the strongest prognostic marker — rising bilirubin = advanced ductopenia = poor prognosis.
-
Always screen for: thyroid disease, Sjögren's, osteoporosis, fat-soluble vitamin deficiency, and HCC (if cirrhotic).
-
UDCA response at 12 months determines prognosis and need for second-line therapy.
High Yield Summary — Management of PBC
-
UDCA is THE first-line treatment: 13–15 mg/kg/day, continued indefinitely. It is the only treatment that modifies the natural history of PBC, with proven survival benefit [1].
-
Assess response at 12 months: ~60% respond adequately. Non-responders need second-line therapy.
-
Second-line: Bezafibrate (PPARα agonist, 400 mg/day) is now preferred; elafibranor and seladelpar are newly approved PPARδ agonists. OCA [1] is an option but has safety concerns (worsens pruritus, contraindicated in decompensated cirrhosis).
-
Pruritus management is stepwise: Cholestyramine (bile acid sequestrant, separate from UDCA) → Rifampicin (enzyme inducer, hepatotoxic) → Naltrexone (opioid antagonist) → IBAT inhibitors → transplant [1].
-
Nutritional support: MCTs for steatorrhoea (bypass bile acid-dependent absorption); Vitamins A and D supplementation (most commonly deficient) [1].
-
Bone disease: Calcium + Vitamin D + Bisphosphonates (alendronate) [1].
-
Liver transplantation: Indicated for bilirubin > 6 mg/dL, decompensated cirrhosis, intractable symptoms, HCC. Excellent outcomes (~85% 5-year survival). PBC can recur in graft (~20%) [1].
-
Hepatic encephalopathy: Lactulose (trap ammonia as NH₄⁺ in gut), dextrose (prevent catabolism), identify and treat precipitants [1].
High Yield Summary — Complications of PBC
Complications are divided into two groups [1]:
A. General complications of cirrhosis (once Stage 4 reached):
- Portal hypertension → Ascites, variceal bleeding, splenomegaly/hypersplenism
- Hepatic encephalopathy — precipitated by protein load, GI bleed, infection, over-diuresis, constipation, drugs
- HCC — surveillance with AFP + USS 6-monthly in all cirrhotic PBC patients
- Hepatorenal syndrome, coagulopathy, SBP
B. PBC-specific complications (can occur at any stage):
- Pruritus — most debilitating symptom; mediated by autotaxin/LPA, bile acids, endogenous opioids; NOT histamine
- Steatorrhoea + fat-soluble vitamin deficiency (A, D, E, K) — from ↓bile acid secretion → ↓micellar absorption; A and D most commonly deficient
- Hepatic osteodystrophy — osteoporosis (retained toxins inhibit osteoblasts) > osteomalacia (vitamin D deficiency); treat with calcium, vitamin D, bisphosphonates
- Hyperlipidaemia — ↑HDL and lipoprotein-X; NOT atherogenic; usually no treatment needed
- Biliary strictures, cholelithiasis, cholangitis — from altered bile composition and periductal fibrosis
- Cholangiocarcinoma — risk lower than PSC but still elevated; screen with USG/MRCP + CA 19-9
Prognostic factors: UDCA non-response, symptomatic presentation, elevated bilirubin, advanced stage, ANA positivity [1]
Pancreatic Cancer
Pancreatic cancer is a highly aggressive malignancy most commonly arising from the exocrine ductal epithelium of the pancreas, often presenting late with obstructive jaundice, weight loss, and pain, carrying a poor prognosis.
Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease.